ReWalk Robotics (LFWD) 10-K 29 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 22, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	ReWalk Robotics Ltd.
Entity Central Index Key	1,607,962
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		12,340,578
Entity Public Float			$ 92,501,337
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS $ in Thousands	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
CURRENT ASSETS:
Cash and cash equivalents	$ 17,869	$ 41,829
Short-term deposit	0	1,667
Trade receivable, net of allowance for doubtful accounts of $144 and $36, respectively	2,146	1,955
Prepaid expenses and other current assets	1,227	756
Inventories	2,534	777
Total current assets	23,776	46,984
LONG-TERM ASSETS
Other long term assets	470	267
Property and equipment, net	1,328	414
Total long-term assets	1,798	681
Total assets	25,574	47,665
CURRENT LIABILITIES:
Trade payables	2,474	1,390
Employees and payroll accruals	1,221	872
Deferred revenues and customers advances	199	77
Other current liabilities	449	769
Other liabilities related to settlement of BIRD Foundation grants (see Note 8c)	0	466
Total current liabilities	4,343	3,574
LONG-TERM LIABILITIES
Deferred revenues	171	172
Other long-term liabilities	140	66
Total long-term liabilities	311	238
Total liabilities	$ 4,654	$ 3,812
COMMITMENTS AND CONTINGENT LIABILITIES
Share capital
Ordinary share of NIS 0.01 par value-Authorized: 250,000,000 shares at December 31, 2015 and 2014; Issued and outstanding: 12,222,583 and 11,978,554 shares at December 31, 2015 and 2014, respectively	$ 33	$ 32
Additional paid-in capital	94,876	92,395
Accumulated deficit	(73,989)	(48,574)
Total shareholders’ equity	20,920	43,853
Total liabilities and shareholders’ equity	$ 25,574	$ 47,665

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) $ in Thousands	Dec. 31, 2015USD ($)shares	Dec. 31, 2015₪ / shares	Dec. 31, 2014USD ($)shares	Dec. 31, 2014₪ / shares	Aug. 26, 2014₪ / sharesshares	Dec. 31, 2013shares
Statement of Financial Position [Abstract]
Trade receivable, allowance for doubtful accounts | $	$ 144		$ 36
Ordinary shares, par value (in USD per share) | ₪ / shares		₪ 0.01		₪ 0.01	₪ 0.01
Ordinary shares, shares authorized	250,000,000		250,000,000		250,000,000	170,413,056
Ordinary shares, shares Issued	12,222,583		11,978,554			185,688
Ordinary shares, shares outstanding	12,222,583		11,978,554			185,688

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenues	$ 3,746	$ 3,951	$ 1,588
Cost of revenues	3,532	4,106	2,017
Expense related to settlement of BIRD Foundation grants	0	466	0
Gross profit (loss)	214	(621)	(429)
Operating expenses:
Research and development, net	5,937	8,563	2,463
Sales and marketing, net	13,056	7,389	4,091
General and administration	6,395	3,352	1,762
Total operating expenses	25,388	19,304	8,316
Operating loss	(25,174)	(19,925)	(8,745)
Financial expenses, net	188	1,698	3,410
Loss before income taxes	(25,362)	(21,623)	(12,155)
Income taxes	53	45	22
Net loss	$ (25,415)	$ (21,668)	$ (12,177)
Net loss per ordinary share, basic and diluted (in USD per share)	$ (2.10)	$ (6.34)	$ (74.53)
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted (in shares)	12,115,038	3,766,694	185,688

STATEMENTS OF CHANGES IN SHAREH

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY) - USD ($) $ in Thousands		Total	Series C convertible preferred shares	Series D convertible preferred shares	Series E convertible preferred shares	Convertible preferred shares	[2]	Convertible preferred sharesSeries C convertible preferred shares	Convertible preferred sharesSeries D convertible preferred shares	Convertible preferred sharesSeries E convertible preferred shares	Ordinary share		Additional paid-in capital	Additional paid-in capitalSeries C convertible preferred shares	Additional paid-in capitalSeries D convertible preferred shares	Additional paid-in capitalSeries E convertible preferred shares	Accumulated deficit
Balance at Dec. 31, 2012		$ (2,264)											$ 12,465				$ (14,729)
Balance (in shares) at Dec. 31, 2012	[1]					161,718					185,688	[3]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of convertible loans into convertible preferred share				$ 9,896											$ 9,896
Conversion of convertible loans into convertible preferred share (in shares)	[1],[2]								81,677
Issuance of convertible preferred shares, net of issuance expense				9,961											9,961
Issuance of convertible preferred shares, net of issuance expense (in shares)	[1],[2]								84,008
Share-based compensation to employees and non employees		215											215
Net loss		(12,177)															(12,177)
Balance at Dec. 31, 2013		5,631											32,537				(26,906)
Balance (in shares) at Dec. 31, 2013	[1]					327,403					185,688	[3]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of warrants into convertible preferred shares			$ 3,825	57										$ 3,825	57
Exercise of warrants into convertible preferred shares (in shares)	[1],[2]							17,705	263
Issuance of convertible preferred shares, net of issuance expense				$ 1,114	$ 7,895										$ 1,114	$ 7,895
Issuance of convertible preferred shares, net of issuance expense (in shares)	[1],[2]								4,131	75,695
Conversion of convertible preferred shares into ordinary shares											$ 22	[1],[3]	(22)
Conversion of convertible preferred shares into ordinary shares (in shares)	[1]					(425,197)					7,838,640	[3]
Issuance of warrants		5,555											5,555
Shares issued	[1],[3]										3,450,000
Issuance of ordinary shares in IPO, net of issuance expenses in an amount of $5,138		36,263									$ 9	[1],[3]	36,254
Share-based compensation to employees and non employees		5,179											5,179
Exercise of warrants into ordinary shares	[1],[3]										157,618
Issuance of ordinary share upon exercise of stock options by employees		2									$ 1	[1],[3]	1
Issuance of ordinary share upon exercise of stock options by employees (in shares)	[1],[3]										346,608
Net loss		(21,668)															(21,668)
Balance at Dec. 31, 2014		43,853									$ 32	[1],[3]	92,395				(48,574)
Balance (in shares) at Dec. 31, 2014	[1]					0					11,978,554	[3]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation to employees and non employees		2,345											2,345
Exercise of warrants into ordinary shares	[1],[3]										49,684
Issuance of ordinary share upon exercise of stock options and RSUs by employees and non employees		137									$ 1	[1],[3]	136
Issuance of ordinary share upon exercise of stock options and RSUs by employees and non employees (shares)	[1],[3]										194,345
Net loss		(25,415)															(25,415)
Balance at Dec. 31, 2015		$ 20,920									$ 33	[1],[3]	$ 94,876				$ (73,989)
Balance (in shares) at Dec. 31, 2015	[1]					0					12,222,583	[3]
[1]	All shares amount have been restated to reflect an 18-for-1 share split, see Note 10a
[2]	The convertible preferred shares consist of several series, see Note 10b.
[3]	The ordinary shares consist of two series, see note 10b.

STATEMENTS OF CHANGES IN SHARE6

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY) (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2015series	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Share split ratio	18
Convertible preferred shares | Series D convertible preferred shares
Issuance cost			$ 204
Convertible preferred shares | Series E convertible preferred shares
Issuance cost		$ 212
Ordinary share
Issuance cost		$ 5,138
Series of equity securities | series	2

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	$ (25,415)	$ (21,668)	$ (12,177)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	438	111	92
Share-based compensation to employees and non employees	2,345	5,179	215
Deferred taxes	(61)	(60)	16
Financial expenses related to convertible loans	0	0	2,166
Revaluation of fair value of warrants to purchase convertible preferred share	0	(776)	1,111
Issuance of Warrants to venture lending	0	835	0
Issuance of Warrants to service provider	0	73	0
Financial expenses resulted from Issuance of Series D preferred shares to related party	0	1,114	0
Changes in assets and liabilities:
Trade receivables, net	(191)	(1,651)	(70)
Prepaid expenses and other current assets	(613)	(440)	(305)
Inventories	(2,525)	196	(413)
Trade payables	1,084	445	10
Employees and payroll accruals	349	308	269
Deferred revenues and advances from customers	121	(72)	272
Other liabilities	(712)	1,105	2
Severance pay, net	0	(18)	12
Net cash used in operating activities	(25,180)	(15,319)	(8,800)
Cash flows from investing activities:
Change in long-term deposits	0	0	7
Investment in short-term deposits	0	(10,000)	0
Maturities of short-term deposits	1,667	8,333	0
Purchase of property and equipment	(584)	(169)	(187)
Net cash provided by (used in) investing activities	1,083	(1,836)	(180)
Cash flows from financing activities:
Issuance of convertible loans	0	0	7,048
Issuance of ordinary share upon exercise of stock options by employees and non employees	137	2	0
Exercise of warrants into Series C and D to convertible preferred shares	0	1,078	0
Issuance of ordinary shares in IPO, net of issuance expenses in an amount of $5,138	0	36,263	0
Net cash provided by financing activities	137	50,124	17,071
Increase (decrease) in cash and cash equivalents	(23,960)	32,969	8,091
Cash and cash equivalents at beginning of period	41,829	8,860	769
Cash and cash equivalents at end of period	17,869	41,829	8,860
Supplemental disclosures of non-cash flow information
Exercise of warrants to purchase preferred shares into Series C and D preferred shares	0	2,804	0
Reclassification of liability warrants to equity warrants	0	5,555	0
Classification of inventory to property and equipment, net	768	0	0
Supplemental disclosures of cash flow information:
Cash paid for income taxes	163	0	123
Series D convertible preferred shares
Cash flows from financing activities:
Issuance of convertible preferred share, including warrants, net	0	0	10,023
Supplemental disclosures of non-cash flow information
Conversion of convertible loan into Series D convertible preferred share	0	0	9,896
Warrants to purchase Series D convertible preferred share issued to service provider	0	0	62
Series E convertible preferred shares
Cash flows from financing activities:
Issuance of convertible preferred share, including warrants, net	$ 0	$ 12,781	$ 0

CONSOLIDATED STATEMENTS OF CAS8

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2014USD ($)
Statement of Cash Flows [Abstract]
Issuance of ordinary shares in IPO, issuance expenses	$ 5,138

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	lk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date. b. RRL has two wholly-owned subsidiaries: (i) ReWalk Robotics Inc. (“RRI”) incorporated under the laws of Delaware on February 15, 2012 and (ii) Argo Medical Technologies GmbH (“AMG”) incorporated under the laws of Germany on January 14, 2013. c. The Company is designing, developing and commercializing the ReWalk system, an innovative exoskeleton that allow wheelchair-bound persons with mobility impairments or other medical conditions to stand and walk once again. The ReWalk system consists of a light wearable brace support suit which integrates motors at the joints, rechargeable batteries, an array of sensors and a computer-based control system to power knee and hip movement. There are currently two types of products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for the clinical rehabilitation environment where it provides valuable exercise and therapy. It also enables individuals to evaluate their capacity for using ReWalk Personal system in the future. d. The Company markets and sells its products directly to institutions and individuals and through third-party distributors. The Company sells its products directly primarily in Germany and the United States, and primarily through distributors in other markets. In its direct markets, the Company has established relationships with rehabilitation centers and the spinal cord injury community, and in its indirect markets, the Company’s distributors maintain these relationships. RRI markets and sells products mainly in the United States and Canada. AMG sell the Company’s products mainly in Germany and Europe. e. In September 2014, the Company completed its Initial Public Offering ("IPO") in which the Company issued and sold 3,000,000 ordinary shares at a public offering price of $12.00 per share and the underwriters exercised their option to purchase an additional 450,000 ordinary shares at the same price per share. The total net proceeds received from the IPO were $36.3 million after deducting underwriting discounts and commissions of $2.7 million and other offering expenses of $2.5 million (refer also to Note 10c). f. The Company depends on one contract manufacturer. Reliance on this vendor makes the Company vulnerable to possible capacity constraints and reduced control over component availability, delivery schedules, manufacturing yields and costs. This vendor account for 24% and 12% of the Company's total trade payables as of December 31, 2015 and 2014 , respectively. g. The Company has incurred losses in the amount of $25,415 during the year ended December 31, 2015 . The Company has an accumulated deficit in the total amount of $73,989 as of December 31, 2015 and negative cash flow from operating activity is in the amount of $25,180 for the year then ended. The Company has sufficient funds to support its operations in 2016 . See note 7 regarding loan received in January 2016.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	SIGNIFICANT ACCOUNTING POLICIES The consolidated financial statements are prepared according to United States generally accepted accounting principles (“U.S. GAAP”), applied on a consistent basis, as follows: a. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company’s management evaluates estimates, including those related to inventories, fair values of share-based awards and warrants, contingent liabilities, provision for warranty, allowance for doubtful account and sales return reserve. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. b. Financial Statements in U.S. Dollars: Most of the revenues and costs of the Company are denominated in United States dollars (“dollars”). Some of the Company’s and its subsidiaries’ revenues and costs are incurred in Euros and New Israeli Shekels (“NIS”). however, the selling prices are linked to the Company’s price list which is determined in dollars, the budget is managed in dollars, financing activities including loans and cash investments, are made in U.S. dollars and the Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and each of its subsidiaries operate. Thus, the dollar is the Company’s and its subsidiaries’ functional and reporting currency. Accordingly, transactions denominated in currencies other than the functional currency are re-measured to the functional currency in accordance with Accounting Standards Codification (“ASC”) No. 830, “Foreign Currency Matters” at the exchange rate at the date of the transaction or the average exchange rate in the relevant reporting period. At the end of each reporting period, financial assets and liabilities are re-measured to the functional currency using exchange rates in effect at the balance sheet date. Non-financial assets and liabilities are re-measured at historical exchange rates. Gains and losses related to re-measurement are recorded as financial income (expense) in the consolidated statements of operations as appropriate. c. Principles of Consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, RRI and AMG. All intercompany transactions and balances have been eliminated upon consolidation. d. Cash Equivalents: Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less, at the date acquired. e. Short term deposits: Short term bank deposits are deposits with original maturities of more than three months but less than one year from the balance sheet date. f. Inventories: Inventories are stated at the lower of cost or market value. Inventory reserves are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates the quantities on hand relative to historical, current and projected sales volume. Based on this evaluation, an impairment charge is recorded when required to write-down inventory to its market value. Cost is determined as follows: Raw materials, auxiliary materials and spare parts - on the basis of raw materials cost on “first in, first out” basis. Finished products - on the basis of raw materials and manufacturing costs on an average basis. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors, including historical usage rates and forecasted sales according to outstanding backlogs. Purchasing requirements and alternative usage are explored within these processes to mitigate inventory exposure. When recorded, the reserves are intended to reduce the carrying value of inventory to its net realizable value. In the years ended December 31, 2015 , 2014 and 2013 , the Company wrote off inventory in the amount of $127 , $76 and $88 , respectively. If actual demand for the Company’s products deteriorates, or market conditions are less favorable than those projected, additional inventory reserves may be required. g. Related party: The Company has a substantial shareholder named Yaskawa Electric Corporation (“YEC”). In September 2013 the Company entered into a share purchase agreement (see Note 10e) and a strategic alliance with YEC, pursuant to which YEC has agreed to distribute the Company’s products, in addition to providing sales, marketing, service and training functions, in Japan, China (including Hong-Kong and Macau), Taiwan, South Korea, Singapore and Thailand. As of December 31, 2015 and 2014 related party receivable in the amount of $242 and $215 , respectively, were included in trade receivable, net. Revenues from YEC during the years ended December 31, 2015 , 2014 and 2013 amounted to $246 , $394 and $88 , respectively. h. Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: % Computer equipment 20-33 (mainly 33) Office furniture and equipment 6 - 10 (mainly 10) Machinery and laboratory equipment 15 Field service units 50 Leasehold improvements Over the shorter of the lease i. Impairment of Long-Lived Assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC No. 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December 31, 2015 , 2014 and 2013 , no impairment losses have been recorded. j. Other long term assets: Other long term assets include long-term prepaid expenses and deposits for office and cars leasing. k. Revenue Recognition: The Company and its subsidiaries generate revenues from sales of products. The Company and its subsidiaries sell their products through a direct sales force and through distributors. Revenues are recognized in accordance with ASC No. 605, “Revenue Recognition” (“ASC 605”), when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed and determinable, collectability is reasonably assured and no further obligations exist. Provisions are made at the time of revenue recognition for any applicable warranty cost expected to be incurred. The timing for revenue recognition amongst the various products and customers is dependent upon satisfaction of such criteria and generally varies from either shipment or delivery to the customer depending on the specific shipping terms of a given transaction, as stipulated in the agreement with each customer. Other than pricing terms which may differ due to the different volumes of purchases between distributors and end-users, there are no material differences in the terms and arrangements involving direct and indirect customers. The Company’s products sold through agreements with distributors are non-exchangeable, non-refundable, non-returnable and without any rights of price protection or share rotation. Accordingly, the Company considers all the distributors to be end-users. The Company generally does not grant a right of return for its products. There have been a few occasions in which the Company experienced a return of its products. Therefore, the Company records reductions to revenue for expected future product returns based on the Company’s historical experience. For systems sold to rehabilitation facilities the Company includes training and considers the elements in the arrangement to be a single unit of accounting. In accordance with ASC 605, the Company has concluded that the training is essential to the functionality of the Company’s systems. Therefore the Company recognizes revenue for the system and training only after delivery in accordance with the agreement delivery terms to the customer and after the training has been completed, once all other revenue recognition criteria have been met. For sales of Personal systems to end users, and for sales of Personal or Rehabilitation systems to third party distributors, the Company does not provide training to the end user as this training is completed by the Rehabilitation centers or by the distributor that have previously completed the ReWalk Training program. Therefore the Company recognizes revenue in such sales upon delivery, assuming the other conditions for revenue recognition have been met. In certain cases, when product arrangements are bundled with extended warranty, the separation of the extended warranty falls under the scope of ASC 605-20-25-1 through 25-6, and the separately price of the extended warranty stated in the agreement is deferred and recognized ratably over the extended warranty period. Deferred revenue includes primarily unearned amounts received in respect of service contracts but not yet recognized as revenues. l. Accounting for Share-Based Compensation: The Company accounts for share-based compensation in accordance with ASC No. 718, “Compensation-Stock Compensation” (“ASC No. 718”). ASC No. 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an Option-Pricing Model (“OPM”). The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards, net of estimated forfeitures. ASC No. 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Estimated forfeitures are based on actual historical pre-vesting forfeitures. The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its share-option awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary share, expected share price volatility and the expected option term. Expected volatility was calculated based upon certain peer companies that the Company considered to be comparable. The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with Staff Accounting Bulletin No. 110, as adequate historical experience is not available to provide a reasonable estimate. The simplified method will continue to apply until enough historical experience is available to provide a reasonable estimate of the expected term. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. The fair value of the ordinary shares underlying the share options has historically been determined by the Company’s board of directors. As prior to the Company’s IPO, there had been no public market for the Company’s ordinary shares, the board of directors determined fair value of the ordinary shares at the time of grant of the option by considering a number of objective and subjective factors including data from other comparable companies, sales of ordinary shares and convertible preferred share to unrelated third parties, operating and financial performance, the lack of liquidity of capital share and general and industry specific economic outlook, among other factors. Since the distributions and participation rights to security holders are different in a sale/liquidation scenario versus an IPO, the valuation of the Company was performed using a weighted average of the values derived from the following scenarios: 1) discounted cash flow (DCF) model, and the OPM method was then employed to allocate the enterprise value amongst the Company’s various equity classes, deriving a fully marketable value per share for the ordinary share; 2) IPO scenario; and 3) Implied value approach. Before the per share value was determined, a discount for lack of marketability and a voting right differential was applied, as applicable, to the ordinary shares and the founders shares. Following the IPO in September 2014, the fair value of ordinary shares is observable as they are publicly traded. The fair value of Restricted Stock Units (RSUs) granted is determined based on the price of the Company's ordinary shares on the date of grant. The fair value for options granted in 2015 , 2014 and 2013 is estimated at the date of grant using a Black-Scholes-Merton option pricing model with the following assumptions: December 31, 2015 2014 2013 Expected volatility 60% 60%-70% 70%-75% Risk-free rate 1.60%-1.95% 1.74%-1.95% 0.95%-2.08% Dividend yield —% —% —% Expected term (in years) 5.73 - 6.11 5.81 - 6.11 6.02 - 6.08 Share price $7.30 - $20.97 $1.49 - $20.77 $3.62 - $5.80 The Company accounts for options granted to consultants and other service providers under ASC No. 718 and ASC No. 505, “Equity-based payments to non-employees.” The fair value of these options was estimated using a Black-Scholes-Merton option-pricing model. In 2015 , 2014 and 2013 the non-cash compensation expenses related to nonemployees were immaterial. The non-cash compensation expenses related to employees and non employees for the years ended December 31, 2015 , 2014 and 2013 amounted to $2,345 , $5,179 and $215 , respectively. m. Research and Development Costs: Research and development costs are charged to the consolidated statement of operations as incurred and are presented net of the amount of any grants we receive for research and development in the period in which we receive the grant. n. Income Taxes The Company accounts for income taxes in accordance with ASC No. 740, “Income Taxes” (“ASC No. 740”), using the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized. ASC No. 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits in its taxes on income. o. Warranty: The Company provides a two -year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. As of December 31, 2015 and 2014 , the provision for warranty amounted to $502 and $387 , respectively, and was presented under other liabilities and long-term liabilities. p. Concentrations of Credit Risks: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade receivables. The Company’s cash and cash equivalents are deposited in major banks in Israel, the United States and Germany. Such deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. The Company maintains cash and cash equivalents with diverse financial institutions and monitors the amount of credit exposure to each financial institution. The Company’s trade receivables are geographically diversified and derived primarily from sales to customers in various countries, mainly in the United States and Europe. Concentration of credit risk with respect to trade receivables is limited by credit limits, ongoing credit evaluation and account monitoring procedures. The Company performs ongoing credit evaluations of its distributors based upon a specific review of all significant outstanding invoices. The Company writes off receivables when they are deemed uncollectible and having exhausted all collection efforts. As of December 31, 2015 and 2014 trade receivables are presented net of $144 and $36 allowance for doubtful accounts, respectively. q. Accrued Severance Pay: Pursuant to Israel’s Severance Pay Law, Israeli employees are entitled to severance pay equal to one month’s salary for each year of employment, or a portion thereof. All of the employees of the RRL elected to be included under section 14 of the Severance Pay Law, 1963 (“section 14”). According to this section, these employees are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 release the Company from any future severance payments (under the above Israeli Severance Pay Law) in respect of those employees; therefore, related assets and liabilities are not presented in the balance sheet. Total Company expenses related to severance pay amounted to $202 , $170 and $126 for the years ended December 31, 2015 , 2014 and 2013 , respectively. r. Fair Value Measurements: Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The three-tiers are defined as follows: • Level 1. Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities; • Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and • Level 3. Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions. The carrying amounts of cash and cash equivalents, short term deposits, trade receivables and trade payables approximate their fair value due to the short-term maturity of such instruments. s. Basic and Diluted Net Loss Per Share: Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding during the period. Diluted net loss per share is computed by giving effect to all potential shares of ordinary shares, including stock options, convertible preferred share warrants, to the extent dilutive, all in accordance with ASC No. 260, “Earning Per Share”. The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share: Year ended December 31 2015 2014 2013 Net loss $ (25,415 ) $ (21,668 ) $ (12,177 ) Convertible preferred shares dividend — (2,229 ) (1,663 ) Net loss attributable to ordinary shares (25,415 ) (23,897 ) (13,840 ) Shares used in computing net loss per ordinary shares, basic and diluted 12,115,038 3,766,694 185,688 Net loss per ordinary share, basic and diluted $ (2.10 ) $ (6.34 ) $ (74.53 ) Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of ordinary shares outstanding would have been anti-dilutive. t. Contingent liabilities The Company accounts for its contingent liabilities in accordance with ASC No. 450, “Contingencies”. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December 31, 2015 and 2014 , the Company is not a party to any ligation that could have a material adverse effect on the Company’s business, financial position, results of operations or cash flows (see Note 8e). u. Government grants Government grants received by the Company relating to categories of operating expenditures are credited to the consolidated statements of operations during the period in which the expenditure to which they relate is charged. Royalty and non-royalty-bearing grants from the Israeli Office of the Chief Scientist (“OCS”), from the Israel-U.S. Binational Industrial Research and Development Foundation (“BIRD”) and from the Israeli Fund for Promoting Overseas Marketing for funding certain approved research and development projects and sales and marketing activities are recognized at the time when the Company is entitled to such grants, on the basis of the related costs incurred, and are included as a deduction from research and development or sales and marketing expenses (see Note 8c). The Company recorded non-royalty-bearing grants in the amount of $0 , $0 and $101 for the years ended December 31, 2015 , 2014 and 2013 , respectively, as part of the sales and marketing expenses. The Company recorded royalty-bearing grants in the amount of $214 , $76 and $0 for the years ended December 31, 2015 , 2014 and 2013 , respectively, as part of the research and development expenses. The Company recorded royalty expenses in the amount of $0 , $204 and $136 for the years ended December 31, 2015 , 2014 and 2013 , respectively, as part of the cost of revenues. On December 2014, the Company recorded a liability of $ 466 as a settlement for the prepayment of amounts due under its agreement with BIRD, representing the full balance of the contingent liability related to grants received (including interest), which was paid during 2015 (see Note 8c). v. New Accounting Pronouncements i. Revenue recognition: In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers. ASU 2014-09 requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. Insurance contracts do not fall within the scope of this ASU. The effective date of ASU 2014-09 is for annual reporting periods beginning after December 15, 2017. In July 2015, the FASB decided to defer by one year the effective date of this ASU and early adoption is permitted for annual reporting periods beginning after December 15, 2016. The ASU has not yet been adopted and the Company is currently evaluating the impact that the adoption of ASU 2014-09 will have on its consolidated financial statements. ii. Going Concern: On August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The ASU is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December 15, 2016, with early adoption permitted. The Company is currently assessing the impact the adoption of ASU 2014-15 will have on its ongoing financial reporting. iii. Inventory: On July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330), Simplifying the Measurement of Inventory, which changes the measurement principle for inventory from the lower of cost or market to lower of cost and net realizable value. Net realizable value is defined as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.” ASU 2015-11 eliminates the guidance that entities consider replacement cost or net realizable value less an approximately normal profit margin in the subsequent measurement of inventory when cost is determined on a first-in, first-out or average cost basis. The provisions of ASU 2015-11 are effective for public entities with fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is in the process of evaluating the impact of the adoption of ASU 2015-11 on its consolidated financial position, consolidated results of operations, and consolidated cash flows iv. Deferred tax: In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic740) Balance Sheet Classification of Deferred Taxes, which will require that the presentation of deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The Company is in the process of evaluating the impact of the adoption of ASU 2015-17 on its consolidated financial statements.

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2015
Prepaid Expense and Other Assets, Current [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	PREPAID EXPENSES AND OTHER CURRENT ASSETS December 31, 2015 2014 Government institutions $ 209 $ 298 Prepaid expenses 316 227 Deposit 43 56 Deferred tax 147 86 Other assets 512 89 $ 1,227 $ 756

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES December 31, 2015 2014 Raw materials $ 450 $ 41 Finished products 2,084 736 $ 2,534 $ 777

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	PROPERTY AND EQUIPMENT, NET December 31, 2015 2014 Cost: Computer equipment $ 656 $ 338 Office furniture and equipment 286 144 Machinery and laboratory equipment 471 235 Field service units 575 — Leasehold improvements 113 32 2,101 749 December 31, 2015 2014 Accumulated depreciation 773 335 Property and equipment, net $ 1,328 $ 414 Depreciation expenses amounted to $ 438 , $ 111 and $ 92 for the years ended December 31, 2015 , 2014 and 2013 , respectively.

SHORT TERM CONVERTIBLE LOANS

SHORT TERM CONVERTIBLE LOANS	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
SHORT TERM CONVERTIBLE LOANS	SHORT TERM CONVERTIBLE LOANS In December 2012, certain of the Company’s existing shareholders signed an agreement to make several convertible loans in an aggregate principal amount of $ 1.5 million with such loans bearing annual interest of 7% . The convertible loans were made during December 2012 and January 2013. Under the loan agreements, the convertible loan amount and accrued interest was to be repaid by the Company to each lender (in proportion to its portion of the principal amount), on December 31, 2013 , unless earlier there was a closing of an investment by any investor(s), the convertible loan amount was to be automatically converted into ordinary shares of the Company at a price per share equal to the price per share paid by the investors, reduced by a percentage equal to 0.167% multiplied by the number of days elapsed from the date of the disbursement of the principal amount by the applicable lender until the conversion date. In no event could the discount exceed 20% . During the period between April and June 2013, a number of the Company’s shareholders and a new investor made additional convertible loans (with the same terms and conditions as the above mentioned convertible loans) in an aggregate principal amount of $6.23 million . The Company recorded the convertible loans as a liability in accordance with ASC No. 480, “Distinguishing Liabilities from Equity” (“ASC No. 480”) as the predominant scenario of the convertible loans embodies an obligation to issue variable number of shares that at inception represents a fixed monitory amount. The fair value is measured at each respective balance sheet date. Upon the closing of the Series D Transaction, on September 24, 2013, all the above convertible loans were converted into 81,677 convertible preferred D shares at a price per share of $96.8 - $103 (which reflects 14.9% - 20% discount rate) in accordance with the series D convertible preferred share purchase agreement. The total amount of convertible loans converted (including accrued interest and revaluation financial expenses) was $9,896 , which was classified to additional paid-in capital in shareholders’ equity (deficiency). Financial expenses related to convertible loans amounted to $0 , $0 and $2,166 in the years ended December 31, 2015 , 2014 and 2013 , respectively (there were no convertible loans in 2015 and 2014 ). Following the conversion of its existing convertible loans as of series D transaction, no additional loans are obtained by the Company.

LOAN AND WARRANTS TO PURCHASE O

LOAN AND WARRANTS TO PURCHASE ORDINARY SHARES (Notes)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
LOANS AND WARRANTS TO PURCHASE ORDINARY SHARES	LOAN AND WARRANTS TO PURCHASE ORDINARY SHARES On December 30, 2015 (the "Agreement Date"), the Company entered into a loan facility agreement (the "Loan Agreement") with Kreos Capital V (Expert Fund) Limited (“Kreos”),pursuant to which Kreos agreed to loan the Company up to $ 20,000 . On January 4, 2016, the Company received a total of $ 12,000 , less $ 415 loan transaction fees and less $ 660 of advance payment (the "Loan"). The Loan is for a period of 36 months and bears annual interest of 10.75% , which is to be paid monthly. The principal of the loan is to be paid in 24 monthly payments, beginning in January 2017, except for the last loan payment which was paid in advance on the Agreement Date, but will be extended to 36 months if the Company raises $ 20,000 or more in connection with the issuance of shares of its capital stock (including debt convertible into shares of our capital stock) prior to the expiration of the 24 -months period. Repayment of the Loan and payment of all other amounts owed to the Lender is to be made in dollars. Pursuant to the Loan Agreement, the Company granted Kreos a first priority security interest over all of its assets, including intellectual property and equity interests in its subsidiaries, subject to certain permitted security interests. In connection with the Loan Agreement, on the agreement date, the Company granted Kreos 119,295 warrants (see note 10h) to purchase ordinary shares at an exercise price of $ 9.64 per share (the "Warrants"). The warrants are exercisable, in whole or in part, at any time prior to the earliest of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly-owned subsidiary of the Company, excluding any transaction in which shareholders of the Company prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. On the Agreement Date, the Company calculated the value of its freestanding Warrants to purchase its ordinary shares in the amount of $ 1,161 (net of $ 42 issuance expenses) , by using the relative fair value method and utilizing an option pricing method. The following assumptions were used to estimate the value of the Company's warrants to purchase ordinary shares: December 30, 2015 Expected volatility 60 % Risk-free rate 2.52 % Dividend yield — % Expected term (in years) 10

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	COMMITMENTS AND CONTINGENT LIABILITIES a. Purchase commitment The Company has contractual obligations to purchase goods from its contract manufacturer. Purchase obligations do not include contracts that may be canceled without penalty. As of December 31, 2015, non-cancelable outstanding obligations amounted to approximately $ 958 . b. Lease commitment: the Company operates from leased facilities in Israel, the Unites States and Germany. These leases expire between 2016 and 2025. The future minimum lease commitments of the Company and its subsidiaries under various non-cancelable operating lease agreements in respect of premises, that are in effect as of December 31, 2015, are as follows: 2016 322 2017 474 2018 498 2019 507 2020 and Thereafter 1,792 Total $ 3,593 Total rent expenses for the years ended December 31, 2015, 2014 and 2013 were $ 260 , $ 168 and $ 156 , respectively. RRL and AMG lease cars for their employees under cancelable operating lease agreements expiring at various dates in 2016-2018. RRL and AMG have an option to be released from these agreements, which may result in penalties in a maximum amount of approximately $ 56 as of December 31, 2015. c. Royalties: The Company’s research and development efforts are financed, in part, through funding from the OCS and BIRD. Since the Company’s inception through December 31, 2015, the Company received funding from the OCS and BIRD in the total amount of $ 740 and $ 500 , respectively. Out of the $ 740 in funding from the OCS, a total amount of $ 340 were royalty bearing grants (as of December 31, 2015, the Company paid royalties to the OCS in the total amount of $ 50 ), while a total amount of $ 400 was received in consideration of 5,237 convertible preferred A shares. The Company is obligated to pay royalties to the OCS, amounting to 3% - 3.5% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received. The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required. The Company was obligated to pay royalties to the BIRD amounting to 5% of the sales of the products and other related revenues generated from such projects, up to 150% of the grants received. During December 2014, the Company recorded a liability of $ 466 as a settlement for the prepayment of amounts due under the agreement with BIRD, representing the full balance of the contingent liability related to grants received (including interest), which was paid in January 2015. Upon making this payment, the Company eliminated all future royalty obligations related to its anticipated revenues. These expenses are included in the cost of revenues in the consolidated statement of operations. For the years ended December 31, 2015, 2014 and 2013, the royalties expenses recorded in cost of revenues amounted to $ 0 , $ 204 and $ 136 respectively. As of December 31, 2015, the contingent liability to the OCS amounted to $ 290 , and there was no contingent liability to the BIRD. The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the OCS. Such approval is not required for the sale or export of any products resulting from such research or development. The OCS, under special circumstances, may approve the transfer of OCS-funded know-how outside Israel, in the following cases: (a) the grant recipient pays to the OCS a portion of the sale price paid in consideration for such OCS-funded know-how or in consideration for the sale of the grant recipient itself, as the case may be, which portion will not exceed six times the amount of the grants received plus interest (or three times the amount of the grant received plus interest, in the event that the recipient of the know-how has committed to retain the R&D activities of the grant recipient in Israel after the transfer); (b) the grant recipient receives know-how from a third party in exchange for its OCS-funded know-how; (c) such transfer of OCS-funded know-how arises in connection with certain types of cooperation in research and development activities; or (d) If such transfer of know-how arises in connection with a liquidation by reason of insolvency or receivership of the grant recipient. d. Liens In connection with the Loan Agreement, the Company granted Kreos a first priority security interest over all of its assets, including intellectual property and equity interests in its subsidiaries, subject to certain permitted security interests. The Company's long-term other assets in the amount of $ 242 have been pledged as security in respect of a guarantee granted to a third party on April 29, 2015 . Such deposit cannot be pledged to others or withdrawn without the consent of such third party. e. Legal Claims: In September 2013, a claim was filed against the Company and the University of Utah Hospital and Medical Center (UUHMC) in the Third Judicial District Court for the County of Salt Lake, State of Utah, in connection with allegations made by a ReWalk user who was injured while using ReWalk. The plaintiff claimed that in April 2013 the ReWalk system malfunctioned while transitioning from sitting to standing mode and sought damages totaling $ 2,900 from the Company and UUHMC for an injury she alleged was caused by such malfunction. In April 2015, the case was settled with the plaintiff. The settlement did not have a material effect on the Company’s business, financial position, results of operations or cash flows.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Financial instruments measured at fair value on a recurring basis include warrants for convertible preferred share. The warrants were classified as a liability in accordance with ASC No. 480 (see Note 11). These warrants were classified as level 3 in the fair value hierarchy since some of the inputs used in the valuation were determined based on management’s assumptions. The fair value of the warrants on the issuance date and on subsequent reporting dates was determined using OPM utilizing the assumptions noted below. The fair value of the underlying preferred share price was determined by the board of directors considering, among others, third party valuations. The valuation of the Company was performed using a DCF model. The OPM method was then employed to allocate the enterprise value among the Company’s various equity classes, deriving a fully marketable value per share for the preferred share. The expected terms of the warrants were based on the remaining contractual expiration period. The expected share price volatility for the shares was determined by examining the historical volatilities of a group of the Company’s industry peers as there is no trading history of the Company’s shares. The risk-free interest rate was calculated using the average of the published interest rates for U.S. Treasury zero-coupon issues with maturities that approximate the expected term. The dividend yield assumption was zero as there is no history of dividend payments. The following assumptions were used to estimate the value of the warrants to purchase series C convertible preferred shares: September 17, 2014 (conversion date) December 31, 2013 Expected volatility 70 % 70 % Risk-free rate 0.1 % 0.1 % Dividend yield — % — % Expected term (in years) 0 1.25 The following assumptions were used to estimate the value of the warrants to purchase series D convertible preferred shares: September 11, 2014 (IPO date) December 31, September 24, 2013 (issuance date) Expected volatility 70 % 70 % 70 % Risk-free rate 1.7 % 0.1 % 0.2 % Dividend yield — % — % — % Expected term (in years) 4.80 1.25 1.50 The following assumptions were used to estimate the value of the warrants to purchase series E convertible preferred shares: September 11, 2014 (IPO date) June 26, 2014 (issuance date) Expected volatility 70 % 70 % Risk-free rate 1.4 % 0.1 % Dividend yield — % — % Expected term (in years) 3.80 4.00 The change in the fair value of warrants to purchase convertible preferred shares liability is summarized below: Balance at beginning of period Issuance of warrants to purchase preferred share Exercise of warrants to purchase preferred share Change in fair value Conversion to Warrants to purchase ordinary share following IPO Balance at end of period December 31, 2014 $ 3,341 $ 5,794 $ (2,804 ) $ (776 ) $ (5,555 ) December 31, 2013 $ 2,168 $ 62 $ — $ 1,111 $ — $ 3,341

SHAREHOLDERS' EQUITY (DEFICIENC

SHAREHOLDERS' EQUITY (DEFICIENCY)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHAREHOLDERS' EQUITY (DEFICIENCY)	SHAREHOLDERS’ EQUITY (DEFICIENCY) a. All ordinary shares, options, exercise prices and loss per share amounts have been adjusted retroactively for all periods presented in these financial statements, to reflect the 17 -to-one bonus share issuance (equivalent to an 18 -for-1 share split) effected on August 26, 2014. b. Composition of convertible preferred share capital and ordinary shares: Authorized Issued and outstanding December 31, December 31, 2015 2014 2013 2015 2014 2013 Number of shares Preferred shares of NIS 0.01 par value: Series A preferred shares — — 11,000 — — 10,677 Series B preferred shares — — 100,000 — — 63,880 Series C-1 preferred shares — — 200,000 — — 67,486 Series C-2 preferred shares — — 40,000 — — 19,675 Series D-1 preferred shares — — 100,000 — — 84,008 Series D-2 preferred shares — — 69,387 — — 69,387 Series D-3 preferred shares — — 10,323 — — 10,323 Series D-4 preferred shares — — 1,967 — — 1,967 Series E preferred shares — — — — — — Total preferred shares — — 532,677 — — 327,403 Ordinary shares of NIS 0.01 par value: Ordinary shares 250,000,000 250,000,000 — 12,222,583 11,978,554 — Ordinary A shares — — 168,613,056 — — 180,000 Ordinary B non-voting shares — — 1,800,000 — — 5,688 Total ordinary shares 250,000,000 250,000,000 170,413,056 12,222,583 11,978,554 185,688 c. Initial Public Offering: In September 2014, the Company completed its IPO in which the Company issued and sold 3,000,000 ordinary shares at a public offering price of $12.00 per share. During the IPO the underwriters received an option to purchase 450,000 ordinary shares of the company at the price of $12.00 for a period of 30 days following the IPO date. During September 2014, the underwriters exercised their option to purchase additional 450,000 ordinary shares at the same IPO price per share. The total net proceeds received from the IPO were $36.3 million after deducting underwriting discounts and commissions of $2.7 million and other offering expenses of $2.5 million . d. 1. Ordinary shares: The ordinary shares of the Company confer on the holders thereof voting rights, rights to receive dividends and rights to participate in distribution of assets upon liquidation after any outstanding preferred shares receive their preference amount. The ordinary A shares and ordinary B shares were restated as ordinary shares in accordance with the following: On August 26, 2014, in a duly convened extraordinary general meeting of the shareholders of the Company, the shareholders (i) duly approved an amendment of the Company's Articles of Association which subsequently entered effect upon the Company's initial public offering, under which the Company's authorized share capital was increased and restated as NIS 2,500,000 divided into 250,000,000 ordinary shares, par value NIS 0.01 , and (ii) ratified an updated capitalization table of the Company, which represented each shareholder's holdings in the Company following the aforementioned restatement of the Company's authorized share capital. 2. Convertible preferred shares: Following the Company's IPO, as described in Note 9c above, all of the Company's convertible preferred shares were automatically converted into 7,838,640 ordinary shares in a conversion ratio of 1 -to-1 e. Preferred Share purchase agreements: The Company entered into a Share Purchase Agreement dated as of September 24, 2013 (the “Series D SPA”) with several existing shareholders and with a new investor, YEC, for the private placement of Series D-1, Series D-2, Series D-3 and Series D-4 convertible preferred shares in connection with the conversion of previously-issued convertible loans. Pursuant to the Series D SPA, the Company issued a total of 84,008 Series D-1 convertible preferred shares for an aggregate purchase price of $ 9,961 (net of $ 204 issuance expenses) and a total of 81,677 Series D-2, Series D-3 and Series D-4 convertible preferred shares, converting convertible loans of $ 9,896 (including financial expenses), including interest. The price per share was $ 121.00 per Series D-1 convertible preferred share, $ 96.80 per Series D-2 convertible preferred share, $ 101.197 per Series D-3 convertible preferred share and $ 103.016 per Series D-4 convertible preferred share. The Series D SPA provides that YEC shall be issued additional shares for no consideration on certain specified dates, beginning on April 1, 2014 and ending on September 1, 2014, if the following two events have not occurred as of such date: (i) receipt of FDA clearance to market ReWalk Personal in the United States and (ii) reimbursement by any German insurance provider of the full cost of at least one ReWalk Personal. An aggregate of 8,264 shares are issuable pursuant to the Series D SPA in connection with the failure to achieve both of these events (see also Note 14). The fair value of those warrants as of the issuance date and as of December 31, 2013 was immaterial. Pursuant to the Series D SPA, the Company issued 1,377 convertible preferred D Shares to YEC on each of April 1, May 1 and June 1, 2014 (a total of 4,131 convertible preferred D shares). Following the issuance of these shares, during the year ended December 31, 2014, the Company recorded their fair value in the amount of $ 1,114 in its consolidated statement of operations under financial expenses, net. The fair value of the Series D convertible preferred shares issued to YEC on each of these dates was determined by the board of directors of the Company considering, among others, third party valuations, and was classified as level 3 in the fair value hierarchy since some of the inputs used in the valuation were determined based on management’s assumptions. The valuation of the Company was performed using a DCF model. The OPM method was then employed to allocate the enterprise value among the Company’s various equity classes, deriving a fully marketable value per share for the preferred share. The expected share price volatility for the shares was determined by examining the historical volatilities of a group of the Company’s industry peers as there is no trading history of the Company’s shares. The risk-free interest rate was calculated using the average of the published interest rates for U.S. Treasury zero-coupon issues with maturities that approximate the expected term. The dividend yield assumption was zero as there is no history of dividend payments. The following assumptions were used to estimate the fair value of the Series D convertible preferred shares issued to YEC on each of these dates: expected volatility- 70% ; Risk-free rate- 0.1% and Dividend yield- 0% . As of June 30, 2014, YEC agreed that both of the above events had been satisfied and as such commencing July 1, 2014 no convertible preferred D Shares will be issued to YEC. On June 26, 2014, the Company entered into a Securities Purchase Agreement with Gabriel Capital Fund (US), L.P. and affiliated entities, and the other parties named therein (the “Series E SPA”). The transaction closed in July 2014. Pursuant to the Series E SPA, the Company issued an aggregate of 75,695 of its preferred E Shares and warrants to purchase an aggregate of 37,850 preferred E Shares (see Note 11d) to Gabriel and the other investors named in the Series E SPA for an aggregate purchase price in cash of $ 13.0 million . The preferred E Shares were issued at a price of $ 171.74 per share. The Company’s articles of association in effect prior to the IPO provided for antidilution protections to certain holders of convertible preferred shares based on the price to the public in the IPO. As a result, the conversion price of certain holders of convertible preferred shares was reduced, and the 75,695 Series E convertible preferred shares are convertible into 1,547,604 ordinary shares. f. Share option plans: On March 30, 2012, the Company’s board of directors adopted the ReWalk Robotics Ltd. 2012 Equity Incentive Plan. On August 19, 2014, the Company’s board of directors adopted the ReWalk Robotics Ltd. 2014 Incentive Compensation Plan (the "Plan"). The Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, cash-based awards, other stock-based awards and dividend equivalents to the Company’s and its affiliates’ respective employees, non-employee directors and consultants. Starting in 2014, the Company granted to directors and the chief executive officer of the Company RSUs under this Plan. An RSU award is an agreement to issue shares of our common stock at the time the award is vested. As of December 31, 2015 and 2014 , the Company had reserved 420,469 and 25,056 shares of ordinary shares, respectively, available for issuance to employees, directors, officers and non-employees of the Company. The share reserve pool will increase on January 1 of each calendar year during the term of the 2014 Plan in an amount equal to the lesser of: (x) 972,000 , (y) 4% of the total number of shares outstanding on December 31 of the immediately preceding calendar year, and (z) an amount determined by the Company's board of directors. The options generally vest over four years. Any option that is forfeited or canceled before expiration becomes available for future grants under the Plan. A summary of employee share options and RSUs activity during the year ended 2015 is as follows: Year Ended December 31, 2015 Number Average exercise price Average remaining contractual life (years) (1) Aggregate intrinsic value (in thousands) Options and RSUs outstanding at the beginning of the year 1,350,846 3.80 8.27 20,373 Options granted 709,105 9.26 RSUs granted 43,466 — Options exercised (158,101 ) $ 0.96 RSUs vested (19,586 ) $ — RSUs forfeited (13,970 ) $ — Options forfeited (58,391 ) $ 3.37 Options and RSUs outstanding at the end of the year 1,853,369 6.12 8.37 17,048 Options and RSUs vested and expected to vest 1,807,787 6.09 8.33 16,699 Options exercisable at the end of the year 649,156 2.65 7.01 7,961 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term. The weighted average grant date fair values of options granted during the year ended December 31, 2015 , 2014 and 2013 were $5.36 , $ 4.74 and $ 2.03 respectively. The weighted average grant date fair values of RSUs granted during the year ended December 31, 2015 and 2014 were $20.77 and $ 20.97 respectively. The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders, which hold options with positive intrinsic value, exercised their options on the last date of the exercise period. Total intrinsic value of options exercised for the year ended December 31, 2015 and 2014 were $2,135 and $38 respectively, no options was exercised during the year ended December 31, 2013 . As of December 31, 2015 , there were $7,864 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2012 , and 2014 Plan. This cost is expected to be recognized over a period of approximately 3 years . The options and RSUs outstanding as of December 31, 2015 have been separated into ranges of exercise price as follows: Range of exercise price Options Outstanding as of December 31, 2015 Weighted average remaining contractual life (years) (1) Options exercisable as of December 31, 2015 Weighted average remaining contractual life (years) (1) —(including options and RSUs) 95,599 3.95 7,338 3.95 $0.82 34,377 5.04 34,377 5.04 $1.32 400,990 6.46 356,166 6.42 $1.48 441,412 8.03 207,155 8.02 $7.30- $8.99 620,027 9.82 — 0.00 $19.62-$20.97 260,964 8.98 44,120 8.96 1,853,369 8.37 649,156 7.01 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term. g. Options issued to consultants: The Company’s outstanding options granted to non-employees as of December 31, 2015 were as follows: Issuance date Options for shares of ordinary share Exercise price per share Options exercisable Exercisable through (number) (number) March 12, 2007 3,454 $ — 3,454 March 12, 2017 h. Warrants to purchase ordinary shares In May 2015 a total of 123,888 warrants were exercised on a cashless basis into 49,684 ordinary shares. The following table summarizes information about warrants outstanding and exercisable as of December 31, 2015: Issuance date Warrants outstanding Exercise Warrants Contractual term (number) (number) July 14, 2014 542,506 $ 10.08 542,506 July 13, 2018 December 30, 2015 119,295 $ 9.64 119,295 The earlier of: (i) December 30, 2025 (ii) a merger, consolidation, or reorganization of the Company. 661,801 661,801 i. Share-based compensation expense for employees and non-employees: The Company recognized non-cash share-based compensation expense in the consolidated statements of operations as follows: Year Ended December 31, 2015 2014 2013 Cost of revenues $ 64 $ 33 $ 5 Research and development, net 425 4,364 73 Sales and marketing, net 571 275 42 General and administrative 1,285 507 95 Total $ 2,345 $ 5,179 $ 215 In May 2012, the Company granted its CEO options to purchase 82,728 ordinary shares at an exercise price of $ 1.32 per share. The options will vest immediately prior to and subject to the occurrence of (i) a merger of the Company into another corporation; (ii) the consummation of a merger, acquisition or sale of the securities of the Company; or (iii) an IPO of the Company’s ordinary shares (“Exit Event”). The above options vesting are also contingent upon market conditions related to the consideration paid to the shareholders of the Company in an Exit Event. The fair value of the above options at the grant date was $ 165 . Following the IPO in September 2014 the Company recorded the $ 165 compensation costs under general and administrative expenses. In accordance with the Company’s articles of association and the Third Amended and Restated Shareholders Agreement, immediately prior to and subject to the occurrence of (i) the consummation of a merger, acquisition or sale of the securities of the Company (“M&A Event”); or (ii) an IPO, the Company’s founder and Chief Technology Officer has the right to receive (i) in case of an M&A Event, 6% of the total proceeds; or (ii) in case of an IPO, for no consideration, shares or immediately exercisable options with cashless exercise in an amount such that the value of his interests equals 6% of the Company’s valuation. Prior to the IPO in September 2014, the Company recorded $ 4,134 compensation costs under research and development expenses in respect thereof.

WARRANTS TO PURCHASE PREFERRED

WARRANTS TO PURCHASE PREFERRED SHARE	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
WARRANTS TO PURCHASE PREFERRED SHARE	WARRANTS TO PURCHASE PREFERRED SHARE Issuance with respect to Warrants to purchase Issuance date Number of warrants Exercise price Contractual term Series C Transaction Preferred C-1 8/2/2011 7,615 $ 105.815 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 3 years from the issuance date (all as stipulated in the specific warrant agreement) Series C Transaction Preferred C-1 1/31/2012 7,231 $ 105.815 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 3 years from the issuance date (all as stipulated in the specific warrant agreement) Series C Transaction Preferred C-1 5/10/2012 4,252 $ 105.815 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 3 years from the issuance date (all as stipulated in the specific warrant agreement) Series C Transaction Preferred C-1 8/20/2012 5,870 $ 105.815 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 3 years from the issuance date (all as stipulated in the specific warrant agreement) Fee agreement with a service provider Preferred D 9/24/2013 600 $ 121 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 5 years from the issuance date (all as stipulated in the specific warrant agreement) Venture loan from Kreos Preferred D 6/19/2014 5,372 $ 206.09 The earlier of: (i) a merger (ii) 5 years from the consummation of an initial public offering and (iii) 10 years from the issuance date (all as stipulated in the specific warrant agreement) Series E Transaction Preferred E 6/26/2014 37,850 $ 206.09 4 years from the issuance date (all as stipulated in the specific warrant agreement) a. In July 26, 2011, the Company signed a series C convertible preferred share purchase agreement (the “Series C Transaction”) with the Company’s shareholders and new investors (collectively the “Investors”), pursuant to which the Company issued to each of the Investors an aggregate amount of 67,486 convertible preferred C-1 shares, at a price per share of $105.815 totaling to approximately $7.1 million . The Investment was made in three installments as follows: (i) the first installment was made at the First Closing, in an aggregate amount of approximately $1 million by means of the issuance of 9,640 convertible preferred C-1 shares (ii) the second installment was made at the Second Closing, subject to the terms of the agreement and fulfillment of the First Milestone, in an aggregate amount of approximately $2.6 million , by means of the issuance of 24,102 convertible preferred C-1 shares and (iii) the third and final installment was made at the Third Closing, subject to the terms of the agreement and fulfillment of the Second Milestone, in an aggregate amount of approximately $3.6 million , by means of the issuance of 33,744 convertible preferred C-1 shares. In conjunction with the Series C Transaction, the Company granted warrants to purchase a number of shares of Series C-1 convertible preferred share upon achieving three milestones, each referred to as closing. At each of the Closings, the investor was granted warrants, at a price per each investment share of $105.815 (i) to purchase an aggregate amount of 7,615 Series C-1 convertible preferred shares to the investors at the First Closing and the holders of C-2 preferred shares, subject to consummation of the First Closing (ii) to purchase an aggregate amount of 7,231 Series C-1 convertible preferred share to the investors at the Second Closing, subject to consummation of the second closing and (iii) to purchase an aggregate amount of 10,122 Series C-1 convertible preferred share to the investors at the third closing, subject to consummation of the third closing. As of December 31, 2013 , all of the three milestones were achieved and all of the above warrants were granted. The warrants to purchase Series C-1 convertible preferred shares were determined to be freestanding instruments and were accounted under ASC No. 480 as a liability in the Company’s financial statements. At each reporting date, the Company re-measures its warrants for convertible preferred shares to fair value using the OPM. Since the warrants to purchase Series C-1 convertible preferred shares were issued in conjunction with the Series C Transaction, the Company first allocated the fair value of the warrants to purchase Series C-1 convertible preferred shares to warrant liability, with the residual proceeds from the Series C Transaction classified as shareholders’ equity (deficiency). On July 30, 2014, all of the 7,615 warrants to purchase series C-1 convertible preferred shares, which were issued on August 2, 2011, were exercised into series C-1 convertible preferred shares as follows: (i) a total of 6,197 warrants were exercised into 6,197 series C-1 convertible preferred shares for cash consideration of $656 and (ii) the remaining 1,418 warrants were exercised on a cashless basis into 721 series C-1 convertible preferred shares. On August 26, 2014, all of the remaining 17,353 warrants to purchase series C-1 convertible preferred shares, which were issued between January 2012 and August 2012, were exercised into series C-1 convertible preferred shares as follows: (i) a total of 3,988 warrants were exercised into 3,988 series C-1 convertible preferred shares for cash consideration of $422 and (ii) the remaining 13,365 warrants were exercised on a cashless basis into 6,799 series C-1 convertible preferred shares. The fair value of the warrants to purchase Series C-1 convertible preferred shares as of June 27, 2011, January 31, 2012, May 10, 2012 and August 20, 2012 (the issuance dates) was $43.09 , $46.74 , $57.68 and $72.26 , per warrant, respectively. b. On May 30, 2013, the Company entered into a fee agreement with one of its service providers, pursuant to which the Company granted the service provider warrants to purchase shares equal to 5% of any shares issued upon cash receipt from an external investor identified by the service provider. As part of the Series D Transaction, on September 30, 2013 the service provider was granted warrants to purchase 600 Series D convertible preferred share. The Company accounted for the warrants to purchase Series D convertible preferred shares under ASC 505 and recorded the warrants at fair value as issuance expense, which was determined to be $62 as of September 24, 2013 (their issuance date), and classified as a liability in the Company’s financial statement. On the August 26, 2014, all of the 600 warrants to purchase series D convertible preferred shares mentioned above, which were issued on September 24, 2013, were exercised on a cashless basis into 263 series D convertible preferred shares. c. On June 19, 2014, the Company entered into a loan agreement with Kreos pursuant to which Kreos agreed to grant a line of credit to the Company of $5.0 million . The line of credit was available for drawdown until September 30, 2014, with a minimum required drawdown of $1.0 million . In October 2014, the Company extended the line of credit until December 31, 2015. Amounts drawn were required to be repaid in 36 monthly installments. The Company did not draw down any funds under this line of credit. Pursuant to the loan agreement, the Company was required to pay a transaction fee of 1.0% of the total amount of the line of credit upon both the execution and the expiration of the loan agreement. In the year ended December 31, 2014 the Company paid and accrued, as part of the Company's financial expenses, a transaction fee expenses an amount of $100 . Pursuant to the loan agreement, the Company granted to Kreos a security interest over all of the Company’s assets, including intellectual property and equity interests in its subsidiaries. In connection with this agreement, the Company granted Kreos warrants to purchase 5,372 Series D-1 convertible preferred shares. The Company accounted for the warrants to purchase Series D-1 convertible preferred shares under ASC No. 480 and recorded the warrants at fair value as financial expense, which was determined to be $835 as of June 19, 2014 (their issuance date), and classified as a liability in the Company’s financial statement. On the September 11, 2014, following the IPO, all of the 5,372 warrants to purchase series D-1 convertible preferred shares mentioned above were converted into warrants to purchase 96,696 ordinary shares. On the September 15, 2014, all of the 96,696 warrants to purchase ordinary shares mentioned above, which were issued on June 19, 2014, were exercised on a cashless basis into 79,200 ordinary shares. d. On June 26, 2014, the Company entered into the series E SPA with Gabriel and the other parties named therein (the “Series E SPA”). The transaction closed in July 2014. Pursuant to the Series E SPA, the Company issued warrants to purchase an aggregate of 37,850 preferred E Shares (which, upon the consummation of the IPO, converted on an 18 -for- 1 basis into warrants to purchase the Company’s ordinary shares) to Gabriel and the other investors named in the Series E SPA. The warrants have an exercise price of $206.09 per share and are exercisable until four years from date of grant, subject to certain adjustments. The Company’s articles of association in effect prior to the IPO provided for antidilution protections to certain holders of convertible preferred shares based on the price to the public in the IPO. Following the IPO, on September 11, 2014 the warrants to purchase 37,850 series D-1 convertible preferred shares mentioned above were converted into warrants to purchase 785,754 ordinary shares. On the September 30, 2014, a total of 26,784 warrants to purchase ordinary shares mentioned above, which were issued on June 26, 2014, were exercised on a cashless basis into 18,192 ordinary shares. On the October 12, 2014, a total of 89,280 warrants to purchase ordinary shares mentioned above, which were issued on June 26, 2014, were exercised on a cashless basis into 60,226 ordinary shares. e. As of December 31, 2013 , the fair value of the warrants to purchase convertible preferred shares was $3,341 . Following the closing of the IPO on September 17, 2014, all outstanding warrants to purchase convertible preferred stock were converted into warrants to purchase ordinary shares which resulted in classification of the remaining warrants liability to additional paid-in capital in the amount of $5,555 . The Company recorded financial expenses (income), net in the amount of $0 , $(776) and $1,111 in 2015 , 2014 and 2013 , respectively, resulting from the revaluation of the warrants to purchase convertible preferred shares.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s subsidiaries are separately taxed under the domestic tax laws of the jurisdiction of incorporation of each entity. a. Corporate tax rates in Israel: Presented hereunder are the tax rates relevant to the Company in the years 2013-2015: The Israeli statutory corporate tax rate was, 25% in 2013 and 26.5% in 2015 and 2014. On January 4, 2016, the statutory tax rate was changed to 25% following a reduction of corporate tax by the government. b. Profit (loss) before taxes on income is comprised as follows: Year Ended December 31, 2015 2014 2013 Domestic $ (25,485 ) $ (21,743 ) $ (12,219 ) Foreign 123 120 64 $ (25,362 ) $ (21,623 ) $ (12,155 ) c. Taxes on income are comprised as follows: Year Ended December 31, 2015 2014 2013 Current $ 114 $ 76 $ 6 Deferred (61 ) (60 ) 16 Prior year taxes — 29 — $ 53 $ 45 $ 22 Year Ended December 31, 2015 2014 2013 Domestic $ — $ — $ — Foreign 53 45 22 $ 53 $ 45 $ 22 d. Deferred income taxes: Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets as of December 31, 2015 and 2014 are derived from temporary differences. In assessing the realization of deferred tax assets, the Company considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. Based on the Company’s history of losses, the Company established a full valuation allowance for RRL. Undistributed earnings of certain subsidiaries as of December 31, 2015 were immaterial. The Company intends to reinvest these earnings indefinitely in the foreign subsidiaries. As a result, the Company has not provided for any deferred income taxes. December 31, 2015 2014 Carry forward tax losses $ 14,961 $ 9,152 Research and Development carry forward expenses-temporary differences 1,176 870 Accrual and reserves 206 153 Deferred tax assets before valuation allowance 16,343 10,175 Valuation allowance (16,196 ) (10,089 ) Net deferred tax assets $ 147 $ 86 e. Reconciliation of the theoretical tax expenses: A reconciliation between the theoretical tax expense, assuming all income is taxed at the statutory tax rate applicable to income of the Company, and the actual tax expense (benefit) as reported in the consolidated statements of operations is as follows: Year Ended December 31, 2015 2014 2013 Loss before taxes, as reported in the consolidated statements of operations $ (25,362 ) $ (21,623 ) $ (12,155 ) Statutory tax rate 26.5 % 26.5 % 25.0 % Theoretical tax benefits on the above amount at the Israeli statutory tax rate $ (6,721 ) $ (5,730 ) $ (3,039 ) Income tax at rate other than the Israeli statutory tax rate 16 12 7 Non-deductible expenses including equity based compensation expenses and other 651 1,864 895 Operating losses and other temporary differences for which valuation allowance was provided 6,107 3,870 2,159 Taxes in respect of prior years — 29 — Actual tax expense $ 53 $ 45 $ 22 f. Foreign tax rates: Taxable income of RRI was subject to tax at the rate of 35% in 2015 , 2014 , and 2013 . Taxable income of AMG was subject to tax at the rate of 30% in 2015 , 2014 , and 2013 . g. Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Investment Law”): Conditions for entitlement to the benefits: Under the Investment Law, in 2012 the Company elected “Beneficiary Enterprise” status which provides certain benefits, including tax exemptions and reduced tax rates. Income not eligible for Beneficiary Enterprise benefits is taxed at a regular rate. Income derived from Beneficiary Enterprise from productive activity will be exempt from tax for ten years from the year in which the Company first has taxable income, providing that 12 years have not passed from the beginning of the year of election. In the event of a dividend distribution from income that is exempt from company tax, as aforementioned, the Company will be required to pay tax of 10% - 25% on that income. In the event of distribution of dividends from the said tax-exempt income, the amount distributed will be subject to corporate tax at the rate ordinarily applicable to the Beneficiary Enterprise’s income. Tax-exempt income generated under the Company’s “Beneficiary Enterprise” program will be subject to taxes upon dividend distribution or complete liquidation. The entitlement to the above benefits is conditional upon the Company’s fulfilling the conditions stipulated by the Law and regulations published thereunder. On December 29, 2010, the Knesset approved an additional amendment to the Law for the Encouragement of Capital Investments, 1959. According to the amendment, a reduced uniform corporate tax rate for exporting industrial enterprises (over 25% ) was established. The reduced tax rate will not be program dependent and will apply to the industrial enterprise’s entire income. The tax rates for industrial enterprises have been reduced gradually over a period of five years as follows: In 2011-2012, the reduced tax rate for development area A will be 10% and for the rest of the country- 15% . In 2013-2014, the reduced tax rate for development area A will be 7% and for the rest of the country- 12.5% . Starting 2015 and thereafter, the reduced tax rate for development area A will be 6% and for the rest of the country- 12% . However, in August 2013, the Israeli Knesset approved an amendment to the Investment Law, pursuant to which such scheduled gradual reduction was repealed beginning in 2014 and the rates for development area A will be 9% and for the rest of the country- 16% in 2014 and thereafter. The Company has examined the effect of the adoption of the Amendment on its financial statements, and as of the date of the publication of the financial statements, the Company estimates that it will not apply the Amendment. The Company’s estimate may change in the future. h. Tax assessments: RRL has final tax assessments up to and including the 2011 tax year. RRI and AMG do not have final tax assessment, since their inception. i. Net operating carry-forward losses for tax purposes: As of December 31, 2015 , RRL has carry-forward losses amounting to approximately $56,500 , which can be carried forward for an indefinite period.

FINANCIAL EXPENSES (INCOME), NE

FINANCIAL EXPENSES (INCOME), NET	12 Months Ended
	Dec. 31, 2015
Other Income and Expenses [Abstract]
FINANCIAL EXPENSES (INCOME), NET	FINANCIAL EXPENSES (INCOME), NET The components of financial expenses (income), net were as follows: Year Ended December 31, 2015 2014 2013 Financial expenses related to convertible loans $ — $ — 2,166 Issuance of warrants to purchase convertible preferred share — 835 — Revaluation of fair value of warrants to purchase convertible preferred shares — (776 ) 1,111 Issuance of convertible preferred shares — 1,114 — Foreign currency transactions and other 170 200 93 Financial expenses related to loan agreement with Kreos — 100 — Issuance cost related to warrants liability — 128 — Bank commissions 36 36 40 (Income) Expenses related to hedging transactions (18 ) 61 — $ 188 $ 1,698 $ 3,410

GEOGRAPHIC INFORMATION AND MAJO

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA	GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Summary information about geographic areas: ASC 280, “Segment Reporting” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment, and derives revenues from selling systems and services (see Note 1 for a brief description of the Company’s business). The following is a summary of revenues within geographic areas: Year Ended December 31, 2015 2014 2013 Revenues based on customer’s location: Israel $ — $ — $ 83 United States 2,439 2,186 941 Europe 820 1,254 476 Asia-Pacific 487 511 88 Total revenues $ 3,746 $ 3,951 $ 1,588 December 31, 2015 2014 Long-lived assets by geographic region: Israel $ 605 $ 279 United States 483 88 Germany 240 47 $ 1,328 $ 414 (*) Long-lived assets are comprised of property and equipment, net. Major customer data as a percentage of total revenues: Year Ended December 31, 2015 2014 2013 Customer A 14.8 % 15 % *) *) Less than 10%

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS a. On January 4, 2016 the Company received from Kreos $ 10,924 net of transaction fees and advance payment. See note 7. b. In January and February 2016 the Company has granted to employees and non employees a total of 37,496 options to purchase the Company's ordinary shares under the Plan.

SIGNIFICANT ACCOUNTING POLICI24

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company’s management evaluates estimates, including those related to inventories, fair values of share-based awards and warrants, contingent liabilities, provision for warranty, allowance for doubtful account and sales return reserve. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
Financial Statements in U.S. Dollars	Financial Statements in U.S. Dollars: Most of the revenues and costs of the Company are denominated in United States dollars (“dollars”). Some of the Company’s and its subsidiaries’ revenues and costs are incurred in Euros and New Israeli Shekels (“NIS”). however, the selling prices are linked to the Company’s price list which is determined in dollars, the budget is managed in dollars, financing activities including loans and cash investments, are made in U.S. dollars and the Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and each of its subsidiaries operate. Thus, the dollar is the Company’s and its subsidiaries’ functional and reporting currency. Accordingly, transactions denominated in currencies other than the functional currency are re-measured to the functional currency in accordance with Accounting Standards Codification (“ASC”) No. 830, “Foreign Currency Matters” at the exchange rate at the date of the transaction or the average exchange rate in the relevant reporting period. At the end of each reporting period, financial assets and liabilities are re-measured to the functional currency using exchange rates in effect at the balance sheet date. Non-financial assets and liabilities are re-measured at historical exchange rates. Gains and losses related to re-measurement are recorded as financial income (expense) in the consolidated statements of operations as appropriate.
Principles of Consolidation	Principles of Consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, RRI and AMG. All intercompany transactions and balances have been eliminated upon consolidation.
Cash Equivalents	Cash Equivalents: Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less, at the date acquired.
Short Term Deposits	Short term deposits: Short term bank deposits are deposits with original maturities of more than three months but less than one year from the balance sheet date.
Inventories	Inventories: Inventories are stated at the lower of cost or market value. Inventory reserves are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates the quantities on hand relative to historical, current and projected sales volume. Based on this evaluation, an impairment charge is recorded when required to write-down inventory to its market value. Cost is determined as follows: Raw materials, auxiliary materials and spare parts - on the basis of raw materials cost on “first in, first out” basis. Finished products - on the basis of raw materials and manufacturing costs on an average basis. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors, including historical usage rates and forecasted sales according to outstanding backlogs. Purchasing requirements and alternative usage are explored within these processes to mitigate inventory exposure. When recorded, the reserves are intended to reduce the carrying value of inventory to its net realizable value. In the years ended December 31, 2015 , 2014 and 2013 , the Company wrote off inventory in the amount of $127 , $76 and $88 , respectively. If actual demand for the Company’s products deteriorates, or market conditions are less favorable than those projected, additional inventory reserves may be required.
Related party	Related party: The Company has a substantial shareholder named Yaskawa Electric Corporation (“YEC”). In September 2013 the Company entered into a share purchase agreement (see Note 10e) and a strategic alliance with YEC, pursuant to which YEC has agreed to distribute the Company’s products, in addition to providing sales, marketing, service and training functions, in Japan, China (including Hong-Kong and Macau), Taiwan, South Korea, Singapore and Thailand. As of December 31, 2015 and 2014 related party receivable in the amount of $242 and $215 , respectively, were included in trade receivable, net. Revenues from YEC during the years ended December 31, 2015 , 2014 and 2013 amounted to $246 , $394 and $88 , respectively.
Property and Equipment	Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: % Computer equipment 20-33 (mainly 33) Office furniture and equipment 6 - 10 (mainly 10) Machinery and laboratory equipment 15 Field service units 50 Leasehold improvements Over the shorter of the lease
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC No. 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December 31, 2015 , 2014 and 2013 , no impairment losses have been recorded.
Long-Term prepaid expenses	Other long term assets: Other long term assets include long-term prepaid expenses and deposits for office and cars leasing.
Revenue Recognition	Revenue Recognition: The Company and its subsidiaries generate revenues from sales of products. The Company and its subsidiaries sell their products through a direct sales force and through distributors. Revenues are recognized in accordance with ASC No. 605, “Revenue Recognition” (“ASC 605”), when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed and determinable, collectability is reasonably assured and no further obligations exist. Provisions are made at the time of revenue recognition for any applicable warranty cost expected to be incurred. The timing for revenue recognition amongst the various products and customers is dependent upon satisfaction of such criteria and generally varies from either shipment or delivery to the customer depending on the specific shipping terms of a given transaction, as stipulated in the agreement with each customer. Other than pricing terms which may differ due to the different volumes of purchases between distributors and end-users, there are no material differences in the terms and arrangements involving direct and indirect customers. The Company’s products sold through agreements with distributors are non-exchangeable, non-refundable, non-returnable and without any rights of price protection or share rotation. Accordingly, the Company considers all the distributors to be end-users. The Company generally does not grant a right of return for its products. There have been a few occasions in which the Company experienced a return of its products. Therefore, the Company records reductions to revenue for expected future product returns based on the Company’s historical experience. For systems sold to rehabilitation facilities the Company includes training and considers the elements in the arrangement to be a single unit of accounting. In accordance with ASC 605, the Company has concluded that the training is essential to the functionality of the Company’s systems. Therefore the Company recognizes revenue for the system and training only after delivery in accordance with the agreement delivery terms to the customer and after the training has been completed, once all other revenue recognition criteria have been met. For sales of Personal systems to end users, and for sales of Personal or Rehabilitation systems to third party distributors, the Company does not provide training to the end user as this training is completed by the Rehabilitation centers or by the distributor that have previously completed the ReWalk Training program. Therefore the Company recognizes revenue in such sales upon delivery, assuming the other conditions for revenue recognition have been met. In certain cases, when product arrangements are bundled with extended warranty, the separation of the extended warranty falls under the scope of ASC 605-20-25-1 through 25-6, and the separately price of the extended warranty stated in the agreement is deferred and recognized ratably over the extended warranty period. Deferred revenue includes primarily unearned amounts received in respect of service contracts but not yet recognized as revenues.
Accounting for Share-Based Compensation	Accounting for Share-Based Compensation: The Company accounts for share-based compensation in accordance with ASC No. 718, “Compensation-Stock Compensation” (“ASC No. 718”). ASC No. 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an Option-Pricing Model (“OPM”). The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards, net of estimated forfeitures. ASC No. 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Estimated forfeitures are based on actual historical pre-vesting forfeitures. The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its share-option awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary share, expected share price volatility and the expected option term. Expected volatility was calculated based upon certain peer companies that the Company considered to be comparable. The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with Staff Accounting Bulletin No. 110, as adequate historical experience is not available to provide a reasonable estimate. The simplified method will continue to apply until enough historical experience is available to provide a reasonable estimate of the expected term. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. The fair value of the ordinary shares underlying the share options has historically been determined by the Company’s board of directors. As prior to the Company’s IPO, there had been no public market for the Company’s ordinary shares, the board of directors determined fair value of the ordinary shares at the time of grant of the option by considering a number of objective and subjective factors including data from other comparable companies, sales of ordinary shares and convertible preferred share to unrelated third parties, operating and financial performance, the lack of liquidity of capital share and general and industry specific economic outlook, among other factors. Since the distributions and participation rights to security holders are different in a sale/liquidation scenario versus an IPO, the valuation of the Company was performed using a weighted average of the values derived from the following scenarios: 1) discounted cash flow (DCF) model, and the OPM method was then employed to allocate the enterprise value amongst the Company’s various equity classes, deriving a fully marketable value per share for the ordinary share; 2) IPO scenario; and 3) Implied value approach. Before the per share value was determined, a discount for lack of marketability and a voting right differential was applied, as applicable, to the ordinary shares and the founders shares. Following the IPO in September 2014, the fair value of ordinary shares is observable as they are publicly traded. The fair value of Restricted Stock Units (RSUs) granted is determined based on the price of the Company's ordinary shares on the date of grant. The fair value for options granted in 2015 , 2014 and 2013 is estimated at the date of grant using a Black-Scholes-Merton option pricing model with the following assumptions: December 31, 2015 2014 2013 Expected volatility 60% 60%-70% 70%-75% Risk-free rate 1.60%-1.95% 1.74%-1.95% 0.95%-2.08% Dividend yield —% —% —% Expected term (in years) 5.73 - 6.11 5.81 - 6.11 6.02 - 6.08 Share price $7.30 - $20.97 $1.49 - $20.77 $3.62 - $5.80 The Company accounts for options granted to consultants and other service providers under ASC No. 718 and ASC No. 505, “Equity-based payments to non-employees.” The fair value of these options was estimated using a Black-Scholes-Merton option-pricing model. In 2015 , 2014 and 2013 the non-cash compensation expenses related to nonemployees were immaterial. The non-cash compensation expenses related to employees and non employees for the years ended December 31, 2015 , 2014 and 2013 amounted to $2,345 , $5,179 and $215 , respectively.
Research and Development Costs	Research and Development Costs: Research and development costs are charged to the consolidated statement of operations as incurred and are presented net of the amount of any grants we receive for research and development in the period in which we receive the grant.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC No. 740, “Income Taxes” (“ASC No. 740”), using the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized. ASC No. 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits in its taxes on income.
Warranty	Warranty: The Company provides a two -year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. As of December 31, 2015 and 2014 , the provision for warranty amounted to $502 and $387 , respectively, and was presented under other liabilities and long-term liabilities.
Concentrations of Credit Risks	Concentrations of Credit Risks: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade receivables. The Company’s cash and cash equivalents are deposited in major banks in Israel, the United States and Germany. Such deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. The Company maintains cash and cash equivalents with diverse financial institutions and monitors the amount of credit exposure to each financial institution. The Company’s trade receivables are geographically diversified and derived primarily from sales to customers in various countries, mainly in the United States and Europe. Concentration of credit risk with respect to trade receivables is limited by credit limits, ongoing credit evaluation and account monitoring procedures. The Company performs ongoing credit evaluations of its distributors based upon a specific review of all significant outstanding invoices. The Company writes off receivables when they are deemed uncollectible and having exhausted all collection efforts. As of December 31, 2015 and 2014 trade receivables are presented net of $144 and $36 allowance for doubtful accounts, respectively.
Accrued Severance Pay	Accrued Severance Pay: Pursuant to Israel’s Severance Pay Law, Israeli employees are entitled to severance pay equal to one month’s salary for each year of employment, or a portion thereof. All of the employees of the RRL elected to be included under section 14 of the Severance Pay Law, 1963 (“section 14”). According to this section, these employees are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 release the Company from any future severance payments (under the above Israeli Severance Pay Law) in respect of those employees; therefore, related assets and liabilities are not presented in the balance sheet. Total Company expenses related to severance pay amounted to $202 , $170 and $126 for the years ended December 31, 2015 , 2014 and 2013 , respectively.
Fair Value Measurements	Fair Value Measurements: Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The three-tiers are defined as follows: • Level 1. Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities; • Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and • Level 3. Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions. The carrying amounts of cash and cash equivalents, short term deposits, trade receivables and trade payables approximate their fair value due to the short-term maturity of such instruments.
Basic and Diluted Net Loss Per Share	Basic and Diluted Net Loss Per Share: Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding during the period. Diluted net loss per share is computed by giving effect to all potential shares of ordinary shares, including stock options, convertible preferred share warrants, to the extent dilutive, all in accordance with ASC No. 260, “Earning Per Share”. The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share: Year ended December 31 2015 2014 2013 Net loss $ (25,415 ) $ (21,668 ) $ (12,177 ) Convertible preferred shares dividend — (2,229 ) (1,663 ) Net loss attributable to ordinary shares (25,415 ) (23,897 ) (13,840 ) Shares used in computing net loss per ordinary shares, basic and diluted 12,115,038 3,766,694 185,688 Net loss per ordinary share, basic and diluted $ (2.10 ) $ (6.34 ) $ (74.53 ) Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of ordinary shares outstanding would have been anti-dilutive.
Contingent liabilities	Contingent liabilities The Company accounts for its contingent liabilities in accordance with ASC No. 450, “Contingencies”. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December 31, 2015 and 2014 , the Company is not a party to any ligation that could have a material adverse effect on the Company’s business, financial position, results of operations or cash flows (see Note 8e).
Government grants	Government grants Government grants received by the Company relating to categories of operating expenditures are credited to the consolidated statements of operations during the period in which the expenditure to which they relate is charged. Royalty and non-royalty-bearing grants from the Israeli Office of the Chief Scientist (“OCS”), from the Israel-U.S. Binational Industrial Research and Development Foundation (“BIRD”) and from the Israeli Fund for Promoting Overseas Marketing for funding certain approved research and development projects and sales and marketing activities are recognized at the time when the Company is entitled to such grants, on the basis of the related costs incurred, and are included as a deduction from research and development or sales and marketing expenses (see Note 8c). The Company recorded non-royalty-bearing grants in the amount of $0 , $0 and $101 for the years ended December 31, 2015 , 2014 and 2013 , respectively, as part of the sales and marketing expenses. The Company recorded royalty-bearing grants in the amount of $214 , $76 and $0 for the years ended December 31, 2015 , 2014 and 2013 , respectively, as part of the research and development expenses. The Company recorded royalty expenses in the amount of $0 , $204 and $136 for the years ended December 31, 2015 , 2014 and 2013 , respectively, as part of the cost of revenues. On December 2014, the Company recorded a liability of $ 466 as a settlement for the prepayment of amounts due under its agreement with BIRD, representing the full balance of the contingent liability related to grants received (including interest), which was paid during 2015 (see Note 8c).
New Accounting Pronouncements	New Accounting Pronouncements i. Revenue recognition: In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers. ASU 2014-09 requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. Insurance contracts do not fall within the scope of this ASU. The effective date of ASU 2014-09 is for annual reporting periods beginning after December 15, 2017. In July 2015, the FASB decided to defer by one year the effective date of this ASU and early adoption is permitted for annual reporting periods beginning after December 15, 2016. The ASU has not yet been adopted and the Company is currently evaluating the impact that the adoption of ASU 2014-09 will have on its consolidated financial statements. ii. Going Concern: On August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The ASU is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December 15, 2016, with early adoption permitted. The Company is currently assessing the impact the adoption of ASU 2014-15 will have on its ongoing financial reporting. iii. Inventory: On July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330), Simplifying the Measurement of Inventory, which changes the measurement principle for inventory from the lower of cost or market to lower of cost and net realizable value. Net realizable value is defined as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.” ASU 2015-11 eliminates the guidance that entities consider replacement cost or net realizable value less an approximately normal profit margin in the subsequent measurement of inventory when cost is determined on a first-in, first-out or average cost basis. The provisions of ASU 2015-11 are effective for public entities with fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is in the process of evaluating the impact of the adoption of ASU 2015-11 on its consolidated financial position, consolidated results of operations, and consolidated cash flows iv. Deferred tax: In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic740) Balance Sheet Classification of Deferred Taxes, which will require that the presentation of deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The Company is in the process of evaluating the impact of the adoption of ASU 2015-17 on its consolidated financial statements.

SIGNIFICANT ACCOUNTING POLICI25

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of property and equipment depreciation rates	Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: % Computer equipment 20-33 (mainly 33) Office furniture and equipment 6 - 10 (mainly 10) Machinery and laboratory equipment 15 Field service units 50 Leasehold improvements Over the shorter of the lease
Schedule of assumption used in determine fair value for options granted under Black-Scholes-Merton option pricing model	The fair value for options granted in 2015 , 2014 and 2013 is estimated at the date of grant using a Black-Scholes-Merton option pricing model with the following assumptions: December 31, 2015 2014 2013 Expected volatility 60% 60%-70% 70%-75% Risk-free rate 1.60%-1.95% 1.74%-1.95% 0.95%-2.08% Dividend yield —% —% —% Expected term (in years) 5.73 - 6.11 5.81 - 6.11 6.02 - 6.08 Share price $7.30 - $20.97 $1.49 - $20.77 $3.62 - $5.80
Schedule of computation of the basic and diluted net loss per ordinary share	The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share: Year ended December 31 2015 2014 2013 Net loss $ (25,415 ) $ (21,668 ) $ (12,177 ) Convertible preferred shares dividend — (2,229 ) (1,663 ) Net loss attributable to ordinary shares (25,415 ) (23,897 ) (13,840 ) Shares used in computing net loss per ordinary shares, basic and diluted 12,115,038 3,766,694 185,688 Net loss per ordinary share, basic and diluted $ (2.10 ) $ (6.34 ) $ (74.53 )

PREPAID EXPENSES AND OTHER CU26

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2015
Prepaid Expense and Other Assets, Current [Abstract]
Schedule of prepaid expenses and other current assets	December 31, 2015 2014 Government institutions $ 209 $ 298 Prepaid expenses 316 227 Deposit 43 56 Deferred tax 147 86 Other assets 512 89 $ 1,227 $ 756

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Schedule of inventories	December 31, 2015 2014 Raw materials $ 450 $ 41 Finished products 2,084 736 $ 2,534 $ 777

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of property and equipment, net	December 31, 2015 2014 Cost: Computer equipment $ 656 $ 338 Office furniture and equipment 286 144 Machinery and laboratory equipment 471 235 Field service units 575 — Leasehold improvements 113 32 2,101 749 December 31, 2015 2014 Accumulated depreciation 773 335 Property and equipment, net $ 1,328 $ 414

LOAN AND WARRANTS TO PURCHASE29

LOAN AND WARRANTS TO PURCHASE ORDINARY SHARES (Tables)	12 Months Ended
	Dec. 31, 2015
Ordinary share
Class of Warrant or Right [Line Items]
Schedule of assumptions used to estimate the value of the warrants to purchase convertible preferred shares	The following assumptions were used to estimate the value of the Company's warrants to purchase ordinary shares: December 30, 2015 Expected volatility 60 % Risk-free rate 2.52 % Dividend yield — % Expected term (in years) 10

COMMITMENTS AND CONTINGENT LI30

COMMITMENTS AND CONTINGENT LIABILITIES COMMITMENTS AND CONTINGENT LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	The future minimum lease commitments of the Company and its subsidiaries under various non-cancelable operating lease agreements in respect of premises, that are in effect as of December 31, 2015, are as follows: 2016 322 2017 474 2018 498 2019 507 2020 and Thereafter 1,792 Total $ 3,593

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2015
FAIR VALUE MEASUREMENTS [Lineitems]
Schedule of change in the fair value of warrants to purchase convertible preferred shares liability	The change in the fair value of warrants to purchase convertible preferred shares liability is summarized below: Balance at beginning of period Issuance of warrants to purchase preferred share Exercise of warrants to purchase preferred share Change in fair value Conversion to Warrants to purchase ordinary share following IPO Balance at end of period December 31, 2014 $ 3,341 $ 5,794 $ (2,804 ) $ (776 ) $ (5,555 ) December 31, 2013 $ 2,168 $ 62 $ — $ 1,111 $ — $ 3,341
Warrants to purchase series C convertible preferred share
FAIR VALUE MEASUREMENTS [Lineitems]
Schedule of assumptions used to estimate the value of the warrants to purchase convertible preferred shares	The following assumptions were used to estimate the value of the warrants to purchase series C convertible preferred shares: September 17, 2014 (conversion date) December 31, 2013 Expected volatility 70 % 70 % Risk-free rate 0.1 % 0.1 % Dividend yield — % — % Expected term (in years) 0 1.25
Warrants to purchase series D convertible preferred shares
FAIR VALUE MEASUREMENTS [Lineitems]
Schedule of assumptions used to estimate the value of the warrants to purchase convertible preferred shares	The following assumptions were used to estimate the value of the warrants to purchase series D convertible preferred shares: September 11, 2014 (IPO date) December 31, September 24, 2013 (issuance date) Expected volatility 70 % 70 % 70 % Risk-free rate 1.7 % 0.1 % 0.2 % Dividend yield — % — % — % Expected term (in years) 4.80 1.25 1.50
Warrants to purchase series E convertible preferred shares
FAIR VALUE MEASUREMENTS [Lineitems]
Schedule of assumptions used to estimate the value of the warrants to purchase convertible preferred shares	The following assumptions were used to estimate the value of the warrants to purchase series E convertible preferred shares: September 11, 2014 (IPO date) June 26, 2014 (issuance date) Expected volatility 70 % 70 % Risk-free rate 1.4 % 0.1 % Dividend yield — % — % Expected term (in years) 3.80 4.00

SHAREHOLDERS' EQUITY (DEFICIE32

SHAREHOLDERS' EQUITY (DEFICIENCY) (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of composition of convertible preferred share capital and ordinary shares capital	Composition of convertible preferred share capital and ordinary shares: Authorized Issued and outstanding December 31, December 31, 2015 2014 2013 2015 2014 2013 Number of shares Preferred shares of NIS 0.01 par value: Series A preferred shares — — 11,000 — — 10,677 Series B preferred shares — — 100,000 — — 63,880 Series C-1 preferred shares — — 200,000 — — 67,486 Series C-2 preferred shares — — 40,000 — — 19,675 Series D-1 preferred shares — — 100,000 — — 84,008 Series D-2 preferred shares — — 69,387 — — 69,387 Series D-3 preferred shares — — 10,323 — — 10,323 Series D-4 preferred shares — — 1,967 — — 1,967 Series E preferred shares — — — — — — Total preferred shares — — 532,677 — — 327,403 Ordinary shares of NIS 0.01 par value: Ordinary shares 250,000,000 250,000,000 — 12,222,583 11,978,554 — Ordinary A shares — — 168,613,056 — — 180,000 Ordinary B non-voting shares — — 1,800,000 — — 5,688 Total ordinary shares 250,000,000 250,000,000 170,413,056 12,222,583 11,978,554 185,688
Summary of employee share option and RSU activity	A summary of employee share options and RSUs activity during the year ended 2015 is as follows: Year Ended December 31, 2015 Number Average exercise price Average remaining contractual life (years) (1) Aggregate intrinsic value (in thousands) Options and RSUs outstanding at the beginning of the year 1,350,846 3.80 8.27 20,373 Options granted 709,105 9.26 RSUs granted 43,466 — Options exercised (158,101 ) $ 0.96 RSUs vested (19,586 ) $ — RSUs forfeited (13,970 ) $ — Options forfeited (58,391 ) $ 3.37 Options and RSUs outstanding at the end of the year 1,853,369 6.12 8.37 17,048 Options and RSUs vested and expected to vest 1,807,787 6.09 8.33 16,699 Options exercisable at the end of the year 649,156 2.65 7.01 7,961 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.
Schedule of options and RSUs outstanding which have been separated into ranges of exercise price	The options and RSUs outstanding as of December 31, 2015 have been separated into ranges of exercise price as follows: Range of exercise price Options Outstanding as of December 31, 2015 Weighted average remaining contractual life (years) (1) Options exercisable as of December 31, 2015 Weighted average remaining contractual life (years) (1) —(including options and RSUs) 95,599 3.95 7,338 3.95 $0.82 34,377 5.04 34,377 5.04 $1.32 400,990 6.46 356,166 6.42 $1.48 441,412 8.03 207,155 8.02 $7.30- $8.99 620,027 9.82 — 0.00 $19.62-$20.97 260,964 8.98 44,120 8.96 1,853,369 8.37 649,156 7.01 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.
Schedule of outstanding options granted to non-employees	The Company’s outstanding options granted to non-employees as of December 31, 2015 were as follows: Issuance date Options for shares of ordinary share Exercise price per share Options exercisable Exercisable through (number) (number) March 12, 2007 3,454 $ — 3,454 March 12, 2017
Schedule of warrants outstanding and exercisable	The following table summarizes information about warrants outstanding and exercisable as of December 31, 2015: Issuance date Warrants outstanding Exercise Warrants Contractual term (number) (number) July 14, 2014 542,506 $ 10.08 542,506 July 13, 2018 December 30, 2015 119,295 $ 9.64 119,295 The earlier of: (i) December 30, 2025 (ii) a merger, consolidation, or reorganization of the Company. 661,801 661,801 Issuance with respect to Warrants to purchase Issuance date Number of warrants Exercise price Contractual term Series C Transaction Preferred C-1 8/2/2011 7,615 $ 105.815 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 3 years from the issuance date (all as stipulated in the specific warrant agreement) Series C Transaction Preferred C-1 1/31/2012 7,231 $ 105.815 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 3 years from the issuance date (all as stipulated in the specific warrant agreement) Series C Transaction Preferred C-1 5/10/2012 4,252 $ 105.815 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 3 years from the issuance date (all as stipulated in the specific warrant agreement) Series C Transaction Preferred C-1 8/20/2012 5,870 $ 105.815 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 3 years from the issuance date (all as stipulated in the specific warrant agreement) Fee agreement with a service provider Preferred D 9/24/2013 600 $ 121 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 5 years from the issuance date (all as stipulated in the specific warrant agreement) Venture loan from Kreos Preferred D 6/19/2014 5,372 $ 206.09 The earlier of: (i) a merger (ii) 5 years from the consummation of an initial public offering and (iii) 10 years from the issuance date (all as stipulated in the specific warrant agreement) Series E Transaction Preferred E 6/26/2014 37,850 $ 206.09 4 years from the issuance date (all as stipulated in the specific warrant agreement)
Schedule of non-cash share-based compensation expense	The Company recognized non-cash share-based compensation expense in the consolidated statements of operations as follows: Year Ended December 31, 2015 2014 2013 Cost of revenues $ 64 $ 33 $ 5 Research and development, net 425 4,364 73 Sales and marketing, net 571 275 42 General and administrative 1,285 507 95 Total $ 2,345 $ 5,179 $ 215

WARRANTS TO PURCHASE PREFERRE33

WARRANTS TO PURCHASE PREFERRED SHARE (Tables)	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of warrants to purchase preferred share	The following table summarizes information about warrants outstanding and exercisable as of December 31, 2015: Issuance date Warrants outstanding Exercise Warrants Contractual term (number) (number) July 14, 2014 542,506 $ 10.08 542,506 July 13, 2018 December 30, 2015 119,295 $ 9.64 119,295 The earlier of: (i) December 30, 2025 (ii) a merger, consolidation, or reorganization of the Company. 661,801 661,801 Issuance with respect to Warrants to purchase Issuance date Number of warrants Exercise price Contractual term Series C Transaction Preferred C-1 8/2/2011 7,615 $ 105.815 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 3 years from the issuance date (all as stipulated in the specific warrant agreement) Series C Transaction Preferred C-1 1/31/2012 7,231 $ 105.815 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 3 years from the issuance date (all as stipulated in the specific warrant agreement) Series C Transaction Preferred C-1 5/10/2012 4,252 $ 105.815 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 3 years from the issuance date (all as stipulated in the specific warrant agreement) Series C Transaction Preferred C-1 8/20/2012 5,870 $ 105.815 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 3 years from the issuance date (all as stipulated in the specific warrant agreement) Fee agreement with a service provider Preferred D 9/24/2013 600 $ 121 The earlier of: (i) a merger (ii) the consummation of an initial public offering and (iii) 5 years from the issuance date (all as stipulated in the specific warrant agreement) Venture loan from Kreos Preferred D 6/19/2014 5,372 $ 206.09 The earlier of: (i) a merger (ii) 5 years from the consummation of an initial public offering and (iii) 10 years from the issuance date (all as stipulated in the specific warrant agreement) Series E Transaction Preferred E 6/26/2014 37,850 $ 206.09 4 years from the issuance date (all as stipulated in the specific warrant agreement)

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of profit (loss) before taxes on income	Profit (loss) before taxes on income is comprised as follows: Year Ended December 31, 2015 2014 2013 Domestic $ (25,485 ) $ (21,743 ) $ (12,219 ) Foreign 123 120 64 $ (25,362 ) $ (21,623 ) $ (12,155 )
Schedule of taxes on income	Taxes on income are comprised as follows: Year Ended December 31, 2015 2014 2013 Current $ 114 $ 76 $ 6 Deferred (61 ) (60 ) 16 Prior year taxes — 29 — $ 53 $ 45 $ 22 Year Ended December 31, 2015 2014 2013 Domestic $ — $ — $ — Foreign 53 45 22 $ 53 $ 45 $ 22
Schedule of deferred income taxes	December 31, 2015 2014 Carry forward tax losses $ 14,961 $ 9,152 Research and Development carry forward expenses-temporary differences 1,176 870 Accrual and reserves 206 153 Deferred tax assets before valuation allowance 16,343 10,175 Valuation allowance (16,196 ) (10,089 ) Net deferred tax assets $ 147 $ 86
Schedule of reconciliation between the theoretical tax expense and the actual tax expense (benefit)	A reconciliation between the theoretical tax expense, assuming all income is taxed at the statutory tax rate applicable to income of the Company, and the actual tax expense (benefit) as reported in the consolidated statements of operations is as follows: Year Ended December 31, 2015 2014 2013 Loss before taxes, as reported in the consolidated statements of operations $ (25,362 ) $ (21,623 ) $ (12,155 ) Statutory tax rate 26.5 % 26.5 % 25.0 % Theoretical tax benefits on the above amount at the Israeli statutory tax rate $ (6,721 ) $ (5,730 ) $ (3,039 ) Income tax at rate other than the Israeli statutory tax rate 16 12 7 Non-deductible expenses including equity based compensation expenses and other 651 1,864 895 Operating losses and other temporary differences for which valuation allowance was provided 6,107 3,870 2,159 Taxes in respect of prior years — 29 — Actual tax expense $ 53 $ 45 $ 22

FINANCIAL EXPENSES (INCOME), 35

FINANCIAL EXPENSES (INCOME), NET (Tables)	12 Months Ended
	Dec. 31, 2015
Other Income and Expenses [Abstract]
Schedule of financial expenses (income), net	The components of financial expenses (income), net were as follows: Year Ended December 31, 2015 2014 2013 Financial expenses related to convertible loans $ — $ — 2,166 Issuance of warrants to purchase convertible preferred share — 835 — Revaluation of fair value of warrants to purchase convertible preferred shares — (776 ) 1,111 Issuance of convertible preferred shares — 1,114 — Foreign currency transactions and other 170 200 93 Financial expenses related to loan agreement with Kreos — 100 — Issuance cost related to warrants liability — 128 — Bank commissions 36 36 40 (Income) Expenses related to hedging transactions (18 ) 61 — $ 188 $ 1,698 $ 3,410

GEOGRAPHIC INFORMATION AND MA36

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Schedule of revenues within geographic areas	The following is a summary of revenues within geographic areas: Year Ended December 31, 2015 2014 2013 Revenues based on customer’s location: Israel $ — $ — $ 83 United States 2,439 2,186 941 Europe 820 1,254 476 Asia-Pacific 487 511 88 Total revenues $ 3,746 $ 3,951 $ 1,588
Schedule of long-lived assets by geographic region	December 31, 2015 2014 Long-lived assets by geographic region: Israel $ 605 $ 279 United States 483 88 Germany 240 47 $ 1,328 $ 414 (*) Long-lived assets are comprised of property and equipment, net.
Schedule of major customer data as a percentage of total revenues	Major customer data as a percentage of total revenues: Year Ended December 31, 2015 2014 2013 Customer A 14.8 % 15 % *) *) Less than 10%

GENERAL (Details)

GENERAL (Details) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2014USD ($)$ / sharesshares	Dec. 31, 2015USD ($)subsidiaryproductmanufacturer	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of wholly-owned subsidiaries | subsidiary		2
Number of products | product		2
Number of shares issued | shares	3,000,000
Offering price (in USD per share) | $ / shares	$ 12
Number of shares issued to underwriters | shares	450,000
Total net proceeds received from the IPO	$ 36,300
Underwriting discounts and commissions	2,700
Other offering expenses	$ 2,500
Net loss		$ 25,415	$ 21,668	$ 12,177
Accumulated deficit		73,989	48,574
Cash flow from operating activity		$ 25,180	$ 15,319	$ 8,800
Trade payables
Vendor concentration [Line Items]
Number of contract manufacturers | manufacturer		1
Vendor concentration | Trade payables
Vendor concentration [Line Items]
Concentration risk (as a percent)		24.00%	12.00%

SIGNIFICANT ACCOUNTING POLICI38

SIGNIFICANT ACCOUNTING POLICIES (Other Narratives) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Inventories:
Wrote off inventory	$ 127,000	$ 76,000	$ 88,000
Impairment of Long-Lived Assets:
Impairment losses	$ 0	0	0
Warranty:
Term of standard warranty	2 years
Provision for warranty accrued	$ 502,000	387,000
Concentrations of Credit Risks:
Allowance for doubtful accounts	$ 144,000	36,000
Accrued Severance Pay:
Percentage of monthly deposit by employees	8.33%
Severance pay expense	$ 202,000	$ 170,000	$ 126,000

SIGNIFICANT ACCOUNTING POLICI39

SIGNIFICANT ACCOUNTING POLICIES (Related party) (Details) - YEC - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Related party [Line Items]
Related party receivable	$ 242	$ 215
Revenues from related party	$ 246	$ 394	$ 88

SIGNIFICANT ACCOUNTING POLICI40

SIGNIFICANT ACCOUNTING POLICIES (Property and Equipment) (Details)	12 Months Ended
	Dec. 31, 2015
Computer equipment | Minimum
Property and Equipment [Line Items]
Depreciation rate	20.00%
Computer equipment | Maximum
Property and Equipment [Line Items]
Depreciation rate	33.00%
Office furniture and equipment | Minimum
Property and Equipment [Line Items]
Depreciation rate	6.00%
Office furniture and equipment | Maximum
Property and Equipment [Line Items]
Depreciation rate	10.00%
Machinery and laboratory equipment
Property and Equipment [Line Items]
Depreciation rate	15.00%
Field service units
Property and Equipment [Line Items]
Depreciation rate	50.00%

SIGNIFICANT ACCOUNTING POLICI41

SIGNIFICANT ACCOUNTING POLICIES (Accounting for Share-Based Compensation) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-cash compensation expenses	$ 2,345	$ 5,179	$ 215
Stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	60.00%
Dividend yield	0.00%	0.00%	0.00%
Stock option | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	70.00%	60.00%	70.00%
Risk-free rate	1.60%	1.74%	0.95%
Expected term	5 years 8 months 23 days	5 years 9 months 22 days	6 years 7 days
Share price (in dollars per share)	$ 7.30	$ 1.49	$ 3.62
Stock option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	75.00%	70.00%	75.00%
Risk-free rate	1.95%	1.95%	2.08%
Expected term	6 years 1 month 10 days	6 years 1 month 10 days	6 years 1 month 10 days
Share price (in dollars per share)	$ 20.97	$ 20.77	$ 5.80

SIGNIFICANT ACCOUNTING POLICI42

SIGNIFICANT ACCOUNTING POLICIES (Basic and Diluted Net Loss Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Net loss	$ (25,415)	$ (21,668)	$ (12,177)
Convertible preferred shares dividend	0	(2,229)	(1,663)
Net loss attributable to ordinary shares	$ (25,415)	$ (23,897)	$ (13,840)
Shares used in computing net loss per ordinary shares, basic and diluted (in shares)	12,115,038	3,766,694	185,688
Net loss per ordinary share, basic and diluted (in USD per share)	$ (2.10)	$ (6.34)	$ (74.53)

SIGNIFICANT ACCOUNTING POLICI43

SIGNIFICANT ACCOUNTING POLICIES (Government grants) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Government grants [Line Items]
Contingent liability		$ 466
BIRD
Government grants [Line Items]
Non-royalty-bearing grants expenses	$ 0	0	$ 101
Royalty-bearing grants expenses	214	76	0
Royalties expenses	$ 0	204	$ 136
Contingent liability		$ 466

PREPAID EXPENSES AND OTHER CU44

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Prepaid Expense and Other Assets, Current [Abstract]
Government institutions	$ 209	$ 298
Prepaid expenses	316	227
Deposit	43	56
Deferred tax	147	86
Other assets	512	89
Prepaid expenses and other current assets	$ 1,227	$ 756

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 450	$ 41
Finished products	2,084	736
Inventories	$ 2,534	$ 777

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
PROPERTY AND EQUIPMENT, NET [Line Items]
Property, plant and equipment, gross	$ 2,101	$ 749
Accumulated depreciation	773	335
Property and equipment, net	1,328	414
Depreciation expenses	438	111	$ 92
Computer equipment
PROPERTY AND EQUIPMENT, NET [Line Items]
Property, plant and equipment, gross	656	338
Office furniture and equipment
PROPERTY AND EQUIPMENT, NET [Line Items]
Property, plant and equipment, gross	286	144
Machinery and laboratory equipment
PROPERTY AND EQUIPMENT, NET [Line Items]
Property, plant and equipment, gross	471	235
Field service units
PROPERTY AND EQUIPMENT, NET [Line Items]
Property, plant and equipment, gross	575	0
Leasehold improvements
PROPERTY AND EQUIPMENT, NET [Line Items]
Property, plant and equipment, gross	$ 113	$ 32

SHORT TERM CONVERTIBLE LOANS (D

SHORT TERM CONVERTIBLE LOANS (Details) - USD ($)	Sep. 24, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
SHORT TERM CONVERTIBLE LOANS [Line Items]
Transaction fee expenses		$ 0	$ 100,000	$ 0
Convertible loans
SHORT TERM CONVERTIBLE LOANS [Line Items]
Loan proceeds					$ 6,230,000	$ 1,500,000
Annual interest rate (as a percent)						7.00%
Debt instrument conversion price calculated based on discount rate considered (as a percent)				0.167%
Total amount of debt converted	$ 9,896,000
Transaction fee expenses		0	0	$ 2,166,000
Outstanding debt		0	$ 0
Additional debt obtained		$ 0
Convertible loans | Minimum
SHORT TERM CONVERTIBLE LOANS [Line Items]
Debt instrument conversion price calculated based on discount rate considered (as a percent)	14.90%
Convertible loans | Maximum
SHORT TERM CONVERTIBLE LOANS [Line Items]
Debt instrument conversion price calculated based on discount rate considered (as a percent)	20.00%			20.00%
Convertible loans | Series D convertible preferred share
SHORT TERM CONVERTIBLE LOANS [Line Items]
Number of shares issued upon conversion of debt instrument	81,677
Convertible loans | Series D convertible preferred share | Minimum
SHORT TERM CONVERTIBLE LOANS [Line Items]
Conversion price (in USD per share)	$ 96.8
Convertible loans | Series D convertible preferred share | Maximum
SHORT TERM CONVERTIBLE LOANS [Line Items]
Conversion price (in USD per share)	$ 103

LOAN AND WARRANTS TO PURCHASE48

LOAN AND WARRANTS TO PURCHASE ORDINARY SHARES Term Loan (Details) - Term Loan - 10.75% Term Loan Due January 2019 - USD ($)	Jan. 04, 2016	Dec. 30, 2015
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 20,000,000
Subsequent event
Debt Instrument [Line Items]
Loan proceeds	$ 12,000,000
Loan transaction fees	415,000
Advance payment	$ 660,000
Annual interest rate (as a percent)	10.75%
Number of monthly payments	24 months
Loan term	36 months
Minimum amount to be raised by issuance of capital stock for extended loan term	$ 20,000,000

LOAN AND WARRANTS TO PURCHASE49

LOAN AND WARRANTS TO PURCHASE ORDINARY SHARES Warrants (Details) $ / shares in Units, $ in Thousands	Dec. 30, 2015USD ($)$ / sharesshares	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	May. 31, 2015shares
Class of Warrant or Right [Line Items]
Transaction fee expenses		$ 0	$ 100	$ 0
Ordinary share
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares) | shares	119,295				123,888
Exercise price (in USD per share) | $ / shares	$ 9.64
Minimum percentage in acquired company required to prevent warrants from becoming exercisable	0.5
Fair value of warrants		$ 1,161
Transaction fee expenses	$ 42

LOAN AND WARRANTS TO PURCHASE50

LOAN AND WARRANTS TO PURCHASE ORDINARY SHARES Warrants Fair Value Assumptions (Details)	Dec. 30, 2015	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Dividend yield (as a percent)		0.00%
Ordinary share
Class of Warrant or Right [Line Items]
Expected volatility (as a percent)	60.00%
Risk-free rate (as a percent)	2.52%
Dividend yield (as a percent)	0.00%
Expected term (in years)	10 years

COMMITMENTS AND CONTINGENT LI51

COMMITMENTS AND CONTINGENT LIABILITIES (Purchase commitment and lease commitment) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Purchase commitment
Outstanding purchase orders	$ 958
Lease commitment:
Total rent expenses	260	$ 168	$ 156
Maximum penalties payable on early release of agreement	$ 56

COMMITMENTS AND CONTINGENT LI52

COMMITMENTS AND CONTINGENT LIABILITIES (Future Minimum Lease Commitments) (Details) $ in Thousands	Dec. 31, 2015USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,016	$ 322
2,017	474
2,018	498
2,019	507
2020 and Thereafter	1,792
Operating Leases, Future Minimum Payments Due	$ 3,593

COMMITMENTS AND CONTINGENT LI53

COMMITMENTS AND CONTINGENT LIABILITIES (Royalties) (Details) $ in Thousands	1 Months Ended	12 Months Ended			174 Months Ended
	Sep. 30, 2014shares	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015USD ($)shares
Royalties [Line Items]
Number of shares issued | shares	3,000,000
Contingent liability			$ 466
OCS
Royalties [Line Items]
Total funding amount received					$ 740
Royalty bearing grants					340
Royalties paid					50
Contingent liability		$ 290			290
Maximum portion of sale price paid in consideration for OCS-funded know-how		6
Transfer of know-how outside Israel approved, if portion of sale price paid by grant receipt does not exceed specified multiplier of grant received		3
OCS | Minimum
Royalties [Line Items]
Royalty (as a percent)		3.00%
OCS | Maximum
Royalties [Line Items]
Royalty (as a percent)		3.50%
Percentage of grant received considered to determine royalty fees		100.00%
OCS | Series A preferred stock
Royalties [Line Items]
Amount received in consideration of convertible preferred shares					$ 400
Number of shares issued | shares					5,237
BIRD
Royalties [Line Items]
Total funding amount received					$ 500
Royalty (as a percent)		5.00%
Contingent liability			466
Royalties expenses		$ 0	$ 204	$ 136
BIRD | Maximum
Royalties [Line Items]
Royalty (as a percent)		150.00%

COMMITMENTS AND CONTINGENT LI54

COMMITMENTS AND CONTINGENT LIABILITIES (Liens) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
Guarantor obligations, collateral pledged	$ 242

COMMITMENTS AND CONTINGENT LI55

COMMITMENTS AND CONTINGENT LIABILITIES (Legal claims) (Details) $ in Thousands	1 Months Ended
	Apr. 30, 2013USD ($)
ReWalk malfunction
Legal Claims [Line Items]
Damages sought value	$ 2,900

FAIR VALUE MEASUREMENTS Additio

FAIR VALUE MEASUREMENTS Additional Detail (Details)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Dividend yield (as a percent)	0.00%

FAIR VALUE MEASUREMENTS (Schedu

FAIR VALUE MEASUREMENTS (Schedule of assumptions used to estimate the value of the warrants to purchase convertible preferred shares) (Details)	Sep. 17, 2014	Sep. 11, 2014	Jun. 26, 2014	Dec. 31, 2013	Sep. 24, 2013	Dec. 31, 2015
Assumptions used to estimate the value of the warrants to purchase convertible preferred shares [lineitems]
Dividend yield (as a percent)						0.00%
Warrants to purchase series C convertible preferred share
Assumptions used to estimate the value of the warrants to purchase convertible preferred shares [lineitems]
Expected volatility (as a percent)	70.00%			70.00%
Risk-free rate (as a percent)	0.10%			0.10%
Dividend yield (as a percent)	0.00%			0.00%
Expected term (in years)	0 years			1 year 3 months
Warrants to purchase series D convertible preferred shares
Assumptions used to estimate the value of the warrants to purchase convertible preferred shares [lineitems]
Expected volatility (as a percent)		70.00%		70.00%	70.00%
Risk-free rate (as a percent)		1.70%		0.10%	0.20%
Dividend yield (as a percent)		0.00%		0.00%	0.00%
Expected term (in years)		4 years 9 months 18 days		1 year 3 months	1 year 6 months
Warrants to purchase series E convertible preferred shares
Assumptions used to estimate the value of the warrants to purchase convertible preferred shares [lineitems]
Expected volatility (as a percent)		70.00%	70.00%
Risk-free rate (as a percent)		1.40%	0.10%
Dividend yield (as a percent)		0.00%	0.00%
Expected term (in years)		3 years 9 months 18 days	4 years

FAIR VALUE MEASUREMENTS (Sche58

FAIR VALUE MEASUREMENTS (Schedule of change in the fair value of warrants to purchase convertible preferred shares liability)(Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period		$ 3,341	$ 2,168
Issuance of warrants to purchase preferred share		5,794	62
Exercise of warrants to purchase preferred share		(2,804)	0
Change in fair value	$ 0	(776)	1,111
Conversion to Warrants to purchase ordinary share following IPO		$ (5,555)	0
Balance at end of period			$ 3,341

SHAREHOLDERS' EQUITY (DEFICIE59

SHAREHOLDERS' EQUITY (DEFICIENCY) (Narrative - Initial Public Offering and Ordinary shares) (Details) ₪ / shares in Units, $ / shares in Units, $ in Thousands	Aug. 26, 2014ILS (₪)₪ / sharesshares	Sep. 30, 2014USD ($)$ / sharesshares	Dec. 31, 2015USD ($)shares	Dec. 31, 2015₪ / shares	Dec. 31, 2014USD ($)shares	Dec. 31, 2014₪ / shares	Dec. 31, 2013shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Bonus share issuance ratio	17
Share split ratio	18		18
Initial public offering [Line Items]
Shares issued | shares		3,000,000
Net proceeds received from IPO		$ 36,300
Underwriting discounts and commissions		2,700
Other offering expenses		$ 2,500
Ordinary shares, authorized amount	₪ 2,500,000		$ 33		$ 32
Ordinary shares, shares authorized | shares	250,000,000		250,000,000		250,000,000		170,413,056
Ordinary shares, par value (in NIS per share) | ₪ / shares	₪ 0.01			₪ 0.01		₪ 0.01
IPO
Initial public offering [Line Items]
Shares issued | shares		3,000,000
Share price (in dollars per share) | $ / shares		$ 12
Net proceeds received from IPO		$ 36,300
Underwriting discounts and commissions		2,700
Other offering expenses		$ 2,500
Option to underwriters
Initial public offering [Line Items]
Shares issued | shares		450,000
Share price (in dollars per share) | $ / shares		$ 12
Underwriter's option period to purchase shares		30 days

SHAREHOLDERS' EQUITY (DEFICIE60

SHAREHOLDERS' EQUITY (DEFICIENCY) (Narrative - Convertible Preferred Shares) (Details) $ / shares in Units, $ in Thousands

Aug. 26, 2014shares

Jul. 01, 2014shares

Jun. 26, 2014USD ($)$ / sharesshares

Jun. 01, 2014shares

May. 01, 2014shares

Apr. 01, 2014shares

Sep. 24, 2013USD ($)milestone$ / sharesshares

Sep. 30, 2014shares

Jun. 01, 2014shares

Aug. 31, 2014shares

Dec. 31, 2015

Dec. 31, 2014USD ($)

Convertible preferred shares [Line Items]

Preferred shares converted into ordinary shares

7,838,640

Conversion ratio

1

Dividend yield (as a percent)

0.00%

Shares issued

3,000,000

Series D preferred shares [Member] | YEC | Share purchase agreement

Convertible preferred shares [Line Items]

Shares converted

0

81,677

8,264

Aggregate purchase price | $

$ 9,896

$ 1,114

Number of events which must occur or additional shares will be issued | milestone

2

Shares issued

1,377

1,377

1,377

4,131

Expected volatility (as a percent)

70.00%

Risk-free rate (as a percent)

0.10%

Dividend yield (as a percent)

0.00%

Series D-1 preferred shares | YEC | Share purchase agreement

Convertible preferred shares [Line Items]

Shares converted

84,008

Aggregate purchase price | $

$ 9,961

Issuance expenses | $

$ 204

Conversion price (in USD per share) | $ / shares

$ 121

Series D-2 preferred shares | YEC | Share purchase agreement

Convertible preferred shares [Line Items]

Conversion price (in USD per share) | $ / shares

96.80

Series D-3 preferred shares | YEC | Share purchase agreement

Convertible preferred shares [Line Items]

Conversion price (in USD per share) | $ / shares

101.197

Series D-4 preferred shares | YEC | Share purchase agreement

Convertible preferred shares [Line Items]

Conversion price (in USD per share) | $ / shares

$ 103.016

Series E preferred shares | Gabriel capital fund (US), L.P. | Securities purchase agreement

Convertible preferred shares [Line Items]

Preferred shares converted into ordinary shares

1,547,604

Shares converted

37,850

Aggregate purchase price | $

$ 13,000

Conversion price (in USD per share) | $ / shares

$ 171.74

Shares issued

75,695

Shares issued

75,695

SHAREHOLDERS' EQUITY (DEFICIE61

SHAREHOLDERS' EQUITY (DEFICIENCY) (Narrative - Share Option Plans) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / shares
Options
Shareholders' equity (deficiency) [Line Items]
Shares reserved for future issuance | shares	420,469	25,056
Weighted average grant date fair values (in USD per share) | $ / shares	$ 5.36	$ 4.74	$ 2.03
Total intrinsic value of options exercised | $	$ 2,135,000	$ 38,000	$ 0
Increase in share reserve pool for future issuance, minimum annual increase | shares	972,000
Increase in share reserve pool for future issuance, annual increase as a percentage of total shares outstanding	0.04
Award vesting period	4 years
RSU
Shareholders' equity (deficiency) [Line Items]
Weighted average grant date fair values (in USD per share) | $ / shares	$ 20.77	$ 20.97
Unrecognized compensation cost | $	$ 7,864,000
Period of recognition of unrecognized compensation cost	3 years

SHAREHOLDERS' EQUITY (DEFICIE62

SHAREHOLDERS' EQUITY (DEFICIENCY) (Schedule of Composition of Convertible Preferred Share Capital and Ordinary Shares Capital) (Details) - ₪ / shares	Dec. 31, 2015	Dec. 31, 2014	Aug. 26, 2014	Dec. 31, 2013
Composition of convertible preferred share capital and ordinary shares capital [Line Items]
Preferred shares, par value (in NIS per share)	₪ 0.01	₪ 0.01
Preferred shares, shares authorized	0	0		532,677
Preferred shares, shares issued	0	0		327,403
Preferred shares, shares outstanding	0	0		327,403
Ordinary shares, par value (in NIS per share)	₪ 0.01	₪ 0.01	₪ 0.01
Ordinary shares, shares authorized	250,000,000	250,000,000	250,000,000	170,413,056
Ordinary shares, shares issued	12,222,583	11,978,554		185,688
Ordinary shares, shares outstanding	12,222,583	11,978,554		185,688
Series A preferred shares
Composition of convertible preferred share capital and ordinary shares capital [Line Items]
Preferred shares, shares authorized	0	0		11,000
Preferred shares, shares issued	0	0		10,677
Preferred shares, shares outstanding	0	0		10,677
Series B preferred shares
Composition of convertible preferred share capital and ordinary shares capital [Line Items]
Preferred shares, shares authorized	0	0		100,000
Preferred shares, shares issued	0	0		63,880
Preferred shares, shares outstanding	0	0		63,880
Series C-1 preferred shares
Composition of convertible preferred share capital and ordinary shares capital [Line Items]
Preferred shares, shares authorized	0	0		200,000
Preferred shares, shares issued	0	0		67,486
Preferred shares, shares outstanding	0	0		67,486
Series C-2 preferred shares
Composition of convertible preferred share capital and ordinary shares capital [Line Items]
Preferred shares, shares authorized	0	0		40,000
Preferred shares, shares issued	0	0		19,675
Preferred shares, shares outstanding	0	0		19,675
Series D-1 preferred shares
Composition of convertible preferred share capital and ordinary shares capital [Line Items]
Preferred shares, shares authorized	0	0		100,000
Preferred shares, shares issued	0	0		84,008
Preferred shares, shares outstanding	0	0		84,008
Series D-2 preferred shares
Composition of convertible preferred share capital and ordinary shares capital [Line Items]
Preferred shares, shares authorized	0	0		69,387
Preferred shares, shares issued	0	0		69,387
Preferred shares, shares outstanding	0	0		69,387
Series D-3 preferred shares
Composition of convertible preferred share capital and ordinary shares capital [Line Items]
Preferred shares, shares authorized	0	0		10,323
Preferred shares, shares issued	0	0		10,323
Preferred shares, shares outstanding	0	0		10,323
Series D-4 preferred shares
Composition of convertible preferred share capital and ordinary shares capital [Line Items]
Preferred shares, shares authorized	0	0		1,967
Preferred shares, shares issued	0	0		1,967
Preferred shares, shares outstanding	0	0		1,967
Series E preferred shares
Composition of convertible preferred share capital and ordinary shares capital [Line Items]
Preferred shares, shares authorized	0	0		0
Preferred shares, shares issued	0	0		0
Preferred shares, shares outstanding	0	0		0
Ordinary shares
Composition of convertible preferred share capital and ordinary shares capital [Line Items]
Ordinary shares, shares authorized	250,000,000	250,000,000		0
Ordinary shares, shares issued	12,222,583	11,978,554		0
Ordinary shares, shares outstanding	12,222,583	11,978,554		0
Ordinary A shares
Composition of convertible preferred share capital and ordinary shares capital [Line Items]
Ordinary shares, shares authorized	0	0		168,613,056
Ordinary shares, shares issued	0	0		180,000
Ordinary shares, shares outstanding	0	0		180,000
Ordinary B non-voting shares
Composition of convertible preferred share capital and ordinary shares capital [Line Items]
Ordinary shares, shares authorized	0	0		1,800,000
Ordinary shares, shares issued	0	0		5,688
Ordinary shares, shares outstanding	0	0		5,688

SHAREHOLDERS' EQUITY (DEFICIE63

SHAREHOLDERS' EQUITY (DEFICIENCY) (Summary of Employee Share Option and RSU Activity ) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Options
Number
Options granted (in shares)	709,105
Options exercised (in shares)	(158,101)
Options forfeited (in shares)	(58,391)
Options exercisable at the end of the year (in shares)	649,156
Average exercise price
Options granted (in dollars per share)	$ 9.26
Exercised (in dollars per share)	0.96
Forfeited (in dollars per share)	3.37
Options exercisable at the end of the year (in dollars per share)	$ 2.65
Average remaining contractual life (years)
Options exercisable at the end of the year	7 years 4 days
Aggregate intrinsic value (in thousands)
Options exercisable at the end of the year	$ 7,961
RSU
Number
RSUs granted (in shares)	43,466
RSUs vested (in shares)	(19,586)
RSUs forfeited (in shares)	(13,970)
Stock Options and RSUs
Number
Options and RSU's outstanding at the beginning of the year (in shares)	1,350,846
Options and RSU's outstanding at the end of the year (in shares)	1,853,369	1,350,846
Options and RSUs vested and expected to vest (in shares)	1,807,787
Average exercise price
Options and RSUs outstanding at the beginning of the year (in dollars per share)	$ 3.80
Options and RSUs outstanding at the end of the year (in dollars per share)	6.12	$ 3.80
Options and RSUs vested and expected to vest (in dollars per share)	$ 6.09
Average remaining contractual life (years)
Options and RSUs outstanding	8 years 4 months 13 days	8 years 3 months 7 days
Options and RSUs vested and expected to vest	8 years 3 months 29 days
Aggregate intrinsic value (in thousands)
Options and RSUs outstanding at beginning of year	$ 20,373
Options and RSUs outstanding at end of year	17,048	$ 20,373
Options and RSUs vested and expected to vest	$ 16,699

SHAREHOLDERS' EQUITY (DEFICIE64

SHAREHOLDERS' EQUITY (DEFICIENCY) (Schedule of Options and RSUs Outstanding Which have been Separated into Ranges of Exercise Price) (Details) - Stock Options and RSUs	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Ranges of Exercise Price [Line Items]
Options outstanding	1,853,369
Weighted average remaining contractual life (years)	8 years 4 months 13 days
Options exercisable	649,156
Weighted average remaining contractual life (years)	7 years 4 days
$ 0
Ranges of Exercise Price [Line Items]
Options outstanding	95,599
Weighted average remaining contractual life (years)	3 years 11 months 12 days
Options exercisable	7,338
Weighted average remaining contractual life (years)	3 years 11 months 12 days
$ 0.82
Ranges of Exercise Price [Line Items]
Range of exercise price (in dollars per share) | $ / shares	$ 0.82
Options outstanding	34,377
Weighted average remaining contractual life (years)	5 years 15 days
Options exercisable	34,377
Weighted average remaining contractual life (years)	5 years 15 days
$ 1.32
Ranges of Exercise Price [Line Items]
Range of exercise price (in dollars per share) | $ / shares	$ 1.32
Options outstanding	400,990
Weighted average remaining contractual life (years)	6 years 5 months 16 days
Options exercisable	356,166
Weighted average remaining contractual life (years)	6 years 5 months 1 day
$ 1.48
Ranges of Exercise Price [Line Items]
Range of exercise price (in dollars per share) | $ / shares	$ 1.48
Options outstanding	441,412
Weighted average remaining contractual life (years)	8 years 11 days
Options exercisable	207,155
Weighted average remaining contractual life (years)	8 years 7 days
$7.30- $8.99
Ranges of Exercise Price [Line Items]
Range of exercise price- minimum (in dollars per share) | $ / shares	$ 7.30
Range of exercise price, maximum (in dollars per share) | $ / shares	$ 8.99
Options outstanding	620,027
Weighted average remaining contractual life (years)	9 years 9 months 26 days
Options exercisable	0
Weighted average remaining contractual life (years)	0 days
$19.62-$20.97
Ranges of Exercise Price [Line Items]
Range of exercise price- minimum (in dollars per share) | $ / shares	$ 19.62
Range of exercise price, maximum (in dollars per share) | $ / shares	$ 20.97
Options outstanding	260,964
Weighted average remaining contractual life (years)	8 years 11 months 23 days
Options exercisable	44,120
Weighted average remaining contractual life (years)	8 years 11 months 16 days

SHAREHOLDERS' EQUITY (DEFICIE65

SHAREHOLDERS' EQUITY (DEFICIENCY) (Schedule of Outstanding Options Granted to Non-employees) (Details) - Nonemployee Stock Option - March 12, 2007	Dec. 31, 2015$ / sharesshares
Shareholders' equity (deficiency) [Line Items]
Options for shares of ordinary share (in shares)	3,454
Exercise price per share (in dollars per shares) | $ / shares	$ 0
Options exercisable (in shares)	3,454

SHAREHOLDERS' EQUITY (DEFICIE66

SHAREHOLDERS' EQUITY (DEFICIENCY) SHAREHOLDER'S EQUITY (DEFICIENCY) (Schedule of Warrants) (Details) - $ / shares	1 Months Ended
	May. 31, 2015	Dec. 31, 2015	Dec. 30, 2015
Ordinary share
Class of Warrant or Right [Line Items]
Issuance of warrants to purchase ordinary shares (in shares)	123,888		119,295
Ordinary shares issued upon exercise of warrants (in shares)	49,684
Warrants outstanding (in shares)		661,801
Exercise price (in USD per share)			$ 9.64
Warrants exercisable (in shares)		661,801
Warrants to Purchase Ordinary Shares Issued on July 14, 2014
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)		542,506
Exercise price (in USD per share)		$ 10.08
Warrants exercisable (in shares)		542,506
Warrants to Purchase Ordinary Shares Issued on December 30, 2015
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)		119,295
Exercise price (in USD per share)		$ 9.64
Warrants exercisable (in shares)		119,295

SHAREHOLDERS' EQUITY (DEFICIE67

SHAREHOLDERS' EQUITY (DEFICIENCY) (Schedule of Non-cash Share-based Compensation Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	$ 2,345	$ 5,179	$ 215
Cost of revenues
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	64	33	5
Research and development, net
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	425	4,364	73
Sales and marketing, net
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	571	275	42
General and administrative
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	$ 1,285	$ 507	$ 95

SHAREHOLDER'S EQUITY (DEFICIENC

SHAREHOLDER'S EQUITY (DEFICIENCY) (Narrative- Share-based compensation expense for employees and non-employees) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Sep. 30, 2014	May. 31, 2012	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			$ 2,345	$ 5,179	$ 215
CEO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)		82,728
Options exercised (in dollars per share)		$ 1.32
Options vested, fair value		$ 165
Right to receive portion of proceeds (percentage)		6.00%
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			1,285	507	95
General and Administrative Expense | CEO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 165
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			$ 425	$ 4,364	$ 73
Research and Development Expense | CEO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 4,134

WARRANTS TO PURCHASE PREFERRE69

WARRANTS TO PURCHASE PREFERRED SHARE (Schedule of Warrants to Purchase Preferred Share) (Details) - $ / shares

12 Months Ended

Dec. 31, 2015

Sep. 11, 2014

Aug. 26, 2014

Jul. 30, 2014

Jun. 26, 2014

Jun. 19, 2014

Sep. 30, 2013

Sep. 24, 2013

Aug. 20, 2012

May. 10, 2012

Jan. 31, 2012

Aug. 02, 2011

Warrants to purchase series C-1 convertible preferred share issued on 08/02/2011

WARRANTS TO PURCHASE PREFERRED SHARE [line Items]

Number of warrants issued (in shares)

7,615

7,615

Exercise price (in USD per share)

$ 105.815

Contractual term determined based on period from the issuance date

3 years

Warrants to purchase series C-1 convertible preferred share issued on 01/31/2012

WARRANTS TO PURCHASE PREFERRED SHARE [line Items]

Number of warrants issued (in shares)

7,231

Exercise price (in USD per share)

$ 105.815

Contractual term determined based on period from the issuance date

3 years

Warrants to purchase series C-1 convertible preferred share issued on 05/10/2012

WARRANTS TO PURCHASE PREFERRED SHARE [line Items]

Number of warrants issued (in shares)

4,252

Exercise price (in USD per share)

$ 105.815

Contractual term determined based on period from the issuance date

3 years

Warrants to purchase series C-1 convertible preferred share issued on 08/20/2012

WARRANTS TO PURCHASE PREFERRED SHARE [line Items]

Number of warrants issued (in shares)

5,870

Exercise price (in USD per share)

$ 105.815

Contractual term determined based on period from the issuance date

3 years

Warrants to purchase series D convertible preferred share issued on 09/24/2013

WARRANTS TO PURCHASE PREFERRED SHARE [line Items]

Number of warrants issued (in shares)

600

600

600

Exercise price (in USD per share)

$ 121

Contractual term determined based on period from the issuance date

5 years

Warrants to purchase series D convertible preferred share issued on 06/19/2014

WARRANTS TO PURCHASE PREFERRED SHARE [line Items]

Number of warrants issued (in shares)

5,372

5,372

Exercise price (in USD per share)

$ 206.09

Contractual term determined based on period from the issuance date

10 years

Contractual term determined based on period from the consummation of an initial public offering

5 years

Warrants to purchase series E convertible preferred share issued on 06/26/2014

WARRANTS TO PURCHASE PREFERRED SHARE [line Items]

Number of warrants issued (in shares)

37,850

Exercise price (in USD per share)

$ 206.09

Contractual term determined based on period from the issuance date

4 years

WARRANTS TO PURCHASE PREFERRE70

WARRANTS TO PURCHASE PREFERRED SHARE (Narrative) (Details)	Oct. 12, 2014shares	Sep. 30, 2014$ / sharesshares	Sep. 17, 2014USD ($)	Sep. 15, 2014shares	Aug. 26, 2014USD ($)shares	Jul. 30, 2014USD ($)shares	Jun. 26, 2014$ / sharesshares	Jun. 19, 2014USD ($)installment$ / sharesshares	Sep. 24, 2013USD ($)$ / sharesshares	Jan. 31, 2012USD ($)$ / sharesshares	Aug. 02, 2011USD ($)$ / sharesshares	Jul. 26, 2011USD ($)milestoneinstallment$ / sharesshares	Sep. 30, 2014$ / sharesshares	Aug. 20, 2012USD ($)$ / sharesshares	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Sep. 11, 2014shares	Sep. 30, 2013shares	May. 30, 2013	May. 10, 2012$ / shares	Jun. 27, 2011$ / shares
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Shares issued													3,000,000
Price of shares issued (in USD per share) | $ / shares		$ 12											$ 12
Cash consideration received upon exercise of warrants | $															$ 0	$ 1,078,000	$ 0
Fair value of the warrants (in USD per warrant) | $ / shares										$ 46.74				$ 72.26							$ 57.68	$ 43.09
Transaction fee expenses | $															0	100,000	0
Fair value of the warrants to purchase convertible preferred shares | $																	3,341,000
Reclassification of liability warrants to equity warrants | $			$ 5,555,000												0	5,555,000	0
Financial expenses (income), net | $															$ 0	$ (776,000)	$ 1,111,000
Line of credit with Kreos
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Maximum borrowing capacity | $								$ 5,000,000
Minimum required drawdown | $								$ 1,000,000
Number of monthly installments in which amounts drawn will be repaid | installment								36
Transaction fee (as a percent)								1.00%
Warrants to purchase series C-1 convertible preferred share issued on 08/02/2011
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Exercise price (in USD per share) | $ / shares											$ 105.815
Number of warrants issued (in shares)						7,615					7,615
Warrants to purchase series C-1 convertible preferred share issued on 01/31/2012
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Exercise price (in USD per share) | $ / shares										$ 105.815
Number of warrants issued (in shares)										7,231
Warrants to purchase series C-1 convertible preferred share issued on 05/10/2012 and 08/20/2012
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Number of warrants issued (in shares)														10,122
Warrants to purchase series C-1 convertible preferred share issued on 08/02/2011, exercisable on cash basis
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Number of warrants issued (in shares)						6,197
Convertible preferred shares issued upon exercise of warrants						6,197
Cash consideration received upon exercise of warrants | $						$ 656,000
Warrants to purchase series C-1 convertible preferred share issued on 08/02/2011, exercisable on cashless basis
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Number of warrants issued (in shares)						1,418
Convertible preferred shares issued upon exercise of warrants						721
Warrants to purchase series C-1 convertible preferred share issued between January 2012 and August 2012
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Number of warrants issued (in shares)					17,353
Warrants to purchase series C-1 convertible preferred share issued between January 2012 and August 2012, exercisable on cash basis
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Number of warrants issued (in shares)					3,988
Convertible preferred shares issued upon exercise of warrants					3,988
Cash consideration received upon exercise of warrants | $					$ 422,000
Warrants to purchase series C-1 convertible preferred share issued between January 2012 and August 2012, exercisable on cashless basis
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Number of warrants issued (in shares)					13,365
Convertible preferred shares issued upon exercise of warrants					6,799
Warrants to purchase series D convertible preferred share issued on 09/24/2013
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Exercise price (in USD per share) | $ / shares									$ 121
Number of warrants issued (in shares)					600				600										600
Convertible preferred shares issued upon exercise of warrants					263
Warrants to purchase shares granted as percentage of shares issued upon cash receipt from an external investor identified by the service provider																				5.00%
Warrants at fair value recorded as issuance expense | $									$ 62,000
Warrants to purchase series D convertible preferred share issued on 06/19/2014
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Exercise price (in USD per share) | $ / shares								$ 206.09
Number of warrants issued (in shares)								5,372										5,372
Warrants at fair value recorded as issuance expense | $								$ 835,000
Warrants to purchase ordinary shares issued upon conversion of series D-1 convertible preferred shares warrants
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Number of warrants issued (in shares)				96,696														96,696
Ordinary shares issued upon exercise of warrants (in shares)				79,200
Warrants to purchase series E convertible preferred share issued on 06/26/2014
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Exercise price (in USD per share) | $ / shares							$ 206.09
Number of warrants issued (in shares)							37,850
Warrants conversion ratio							18
Warrants, exercise period							4 years
Warrants to purchase ordinary shares issued upon conversion of series E convertible preferred shares warrants
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Number of warrants issued (in shares)	89,280	26,784											26,784					785,754
Ordinary shares issued upon exercise of warrants (in shares)	60,226	18,192
Convertible preferred C-1 shares
WARRANTS TO PURCHASE PREFERRED SHARE [line Items]
Shares issued										24,102	9,640	67,486		33,744
Price of shares issued (in USD per share) | $ / shares												$ 105.815
Aggregate amount received upon issuance of shares | $										$ 2,600,000	$ 1,000,000	$ 7,100,000		$ 3,600,000
Number of installments into which investments was made | installment												3
Number of milestones | milestone												3
Exercise price (in USD per share) | $ / shares												$ 105.815

INCOME TAXES (Narratives) (Deta

INCOME TAXES (Narratives) (Details) $ in Thousands	Jan. 04, 2016	Dec. 31, 2015USD ($)	Dec. 31, 2014	Dec. 31, 2013
INCOME TAXES [Line items]
Statutory tax rate (as a percent)		26.50%	26.50%	25.00%
Beneficiary enterprise from productive activity, tax exemption period		10 years
Beneficiary enterprise from productive activity, maximum time from period of election for tax exemption		12 years
Carry-forward losses		$ 56,500
RRI
INCOME TAXES [Line items]
Statutory tax rate (as a percent)		35.00%	35.00%	35.00%
AMG
INCOME TAXES [Line items]
Statutory tax rate (as a percent)		30.00%	30.00%	30.00%
Subsequent event
INCOME TAXES [Line items]
Statutory tax rate (as a percent)	25.00%
Minimum
INCOME TAXES [Line items]
Beneficiary enterprise from productive activity, tax rate on dividend distributions from tax exempt Income		0.1
Maximum
INCOME TAXES [Line items]
Beneficiary enterprise from productive activity, tax rate on dividend distributions from tax exempt Income		0.25

INCOME TAXES (Schedule of profi

INCOME TAXES (Schedule of profit (loss) before taxes on income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Domestic	$ (25,485)	$ (21,743)	$ (12,219)
Foreign	123	120	64
Profit (loss) before taxes	$ (25,362)	$ (21,623)	$ (12,155)

INCOME TAXES (Schedule of taxes

INCOME TAXES (Schedule of taxes on income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Current	$ 114	$ 76	$ 6
Deferred	(61)	(60)	16
Prior year taxes	0	29	0
Taxes on income	$ 53	$ 45	$ 22

INCOME TAXES (Schedule of tax74

INCOME TAXES (Schedule of taxes on income by jurisdiction) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Domestic	$ 0	$ 0	$ 0
Foreign	53	45	22
Taxes on income	$ 53	$ 45	$ 22

INCOME TAXES (Schedule of defer

INCOME TAXES (Schedule of deferred income taxes) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Carry forward tax losses	$ 14,961	$ 9,152
Research and Development carry forward expenses-temporary differences	1,176	870
Accrual and reserves	206	153
Deferred tax assets before valuation allowance	16,343	10,175
Valuation allowance	(16,196)	(10,089)
Net deferred tax assets	$ 147	$ 86

INCOME TAXES (Schedule of recon

INCOME TAXES (Schedule of reconciliation between the theoretical tax expense and the actual tax expense (benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Loss before taxes, as reported in the consolidated statements of operations	$ (25,362)	$ (21,623)	$ (12,155)
Statutory tax rate	26.50%	26.50%	25.00%
Theoretical tax benefits on the above amount at the Israeli statutory tax rate	$ (6,721)	$ (5,730)	$ (3,039)
Income tax at rate other than the Israeli statutory tax rate	16	12	7
Non-deductible expenses including equity based compensation expenses and other	651	1,864	895
Operating losses and other temporary differences for which valuation allowance was provided	6,107	3,870	2,159
Taxes in respect of prior years	0	29	0
Taxes on income	$ 53	$ 45	$ 22

FINANCIAL EXPENSES (INCOME), 77

FINANCIAL EXPENSES (INCOME), NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Other Income and Expenses [Abstract]
Financial expenses related to convertible loans	$ 0	$ 0	$ 2,166
Issuance of warrants to purchase convertible preferred share	0	835	0
Revaluation of fair value of warrants to purchase convertible preferred share	0	(776)	1,111
Issuance of convertible preferred shares	0	1,114	0
Foreign currency transactions and other	170	200	93
Financial expenses related to loan agreement with Kreos	0	100	0
Issuance cost related to warrants liability	0	128	0
Bank commissions	36	36	40
(Income) Expenses related to hedging transactions	(18)	61	0
Financial expenses (income), net	$ 188	$ 1,698	$ 3,410

GEOGRAPHIC INFORMATION AND MA78

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Additional Information (Details)	12 Months Ended
	Dec. 31, 2015segment
Segment Reporting [Abstract]
Number of reportable segments	1

GEOGRAPHIC INFORMATION AND MA79

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Schedule of revenues and long-lived assets by geographic region) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	$ 3,746	$ 3,951	$ 1,588
Long-lived assets	1,328	414
Israel
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	0	0	83
Long-lived assets	605	279
United States
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	2,439	2,186	941
Long-lived assets	483	88
Europe
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	820	1,254	476
Asia-Pacific
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	487	511	$ 88
Germany
Summary of revenues and long-lived assets by geographic region [Line items]
Long-lived assets	$ 240	$ 47

GEOGRAPHIC INFORMATION AND MA80

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Schedule of major customer data as a percentage of total revenues) (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenue | Customer concentration | Customer A
Major customer data as a percentage of total revenues [Line items]
Concentration risk (as a percent)	14.80%	15.00%

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($) $ in Thousands	Jan. 04, 2016	Feb. 25, 2016	Dec. 31, 2015
10.75% Term Loan Due January 2019 | Term Loan | Subsequent event
SUBSEQUENT EVENTS [Line items]
Loan proceeds	$ 10,924
Stock option
SUBSEQUENT EVENTS [Line items]
Options granted (in shares)			709,105
Stock option | Subsequent event
SUBSEQUENT EVENTS [Line items]
Options granted (in shares)		37,496